DK2872147T3 - Fremgangsmåde til fremstilling af kirale oligonukleotider - Google Patents

Fremgangsmåde til fremstilling af kirale oligonukleotider Download PDF

Info

Publication number: DK2872147T3
Authority: DK; Denmark
Prior art keywords: preparation; chiral oligonucleotides; chiral; oligonucleotides
Prior art date: 2012-07-13

Application number

DK13817244.0T

Other languages

English (en)

Inventor

David Butler

Naoki Iwamoto

Ivan Zlatev

Nenad Svrzikapa

Gregory L Verdine

Meena

Original Assignee

Wave Life Sciences Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-07-13

Filing date

2013-07-12

Publication date

2023-02-20

2013-07-12 Application filed by Wave Life Sciences Ltd filed Critical Wave Life Sciences Ltd

2023-02-20 Application granted granted Critical

2023-02-20 Publication of DK2872147T3 publication Critical patent/DK2872147T3/da

Links

108091034117 Oligonucleotide Proteins 0.000 title 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/02—Phosphorylation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/30—Production chemically synthesised

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
General Health & Medical Sciences (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Analytical Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Gastroenterology & Hepatology (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Massaging Devices (AREA)
Paper (AREA)
Extrusion Moulding Of Plastics Or The Like (AREA)

DK13817244.0T 2012-07-13 2013-07-12 Fremgangsmåde til fremstilling af kirale oligonukleotider DK2872147T3 (da)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US201261671655P	2012-07-13	2012-07-13
US201261671656P	2012-07-13	2012-07-13
US201261671722P	2012-07-14	2012-07-14
US201261671724P	2012-07-14	2012-07-14
PCT/US2013/050407 WO2014012081A2 (en)	2012-07-13	2013-07-12	Chiral control

Publications (1)

Publication Number	Publication Date
DK2872147T3 true DK2872147T3 (da)	2023-02-20

Family

ID=49916709

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK13817244.0T DK2872147T3 (da)	2012-07-13	2013-07-12	Fremgangsmåde til fremstilling af kirale oligonukleotider

Country Status (16)

Country	Link
US (4)	US9982257B2 (da)
EP (2)	EP2872147B1 (da)
JP (4)	JP6453212B2 (da)
KR (4)	KR102213609B1 (da)
CN (2)	CN112007045B (da)
AU (5)	AU2013289880B2 (da)
CA (1)	CA2878945A1 (da)
CL (1)	CL2015000092A1 (da)
DK (1)	DK2872147T3 (da)
ES (1)	ES2940887T3 (da)
IL (1)	IL236621B (da)
MX (1)	MX2015000577A (da)
PL (1)	PL2872147T3 (da)
RU (1)	RU2015104762A (da)
SG (3)	SG10201912895PA (da)
WO (1)	WO2014012081A2 (da)

Families Citing this family (160)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN102282155B (zh)	2008-12-02	2017-06-09	日本波涛生命科学公司	磷原子修饰的核酸的合成方法
RU2612521C2 (ru)	2009-07-06	2017-03-09	Онтории, Инк.	Новые пролекарства нуклеиновых кислот и способы их применения
JP5868324B2 (ja)	2010-09-24	2016-02-24	株式会社Wave Life Sciences Japan	不斉補助基
CA2817960C (en)	2010-11-17	2020-06-09	Ionis Pharmaceuticals, Inc.	Modulation of alpha synuclein expression
CN103796657B (zh)	2011-07-19	2017-07-11	波涛生命科学有限公司	合成官能化核酸的方法
EP2831232A4 (en)	2012-03-30	2015-11-04	Univ Washington	METHOD FOR MODULATING TAU EXPRESSION TO REDUCE PROBLEMS AND MODIFY A NEURODEGENERATIVE SYNDROME
PL2872485T3 (pl)	2012-07-13	2021-05-31	Wave Life Sciences Ltd.	Asymetryczna grupa pomocnicza
KR102213609B1 (ko)	2012-07-13	2021-02-08	웨이브 라이프 사이언시스 리미티드	키랄 제어
CA2879066C (en)	2012-07-13	2019-08-13	Shin Nippon Biomedical Laboratories, Ltd.	Chiral nucleic acid adjuvant
CN105264091B (zh)	2013-03-14	2020-02-28	Ionis制药公司	用于调节tau表达的组合物和方法
TW202246503A (zh)	2013-07-19	2022-12-01	美商百健Ｍａ公司	用於調節τ蛋白表現之組合物
US10322173B2 (en)	2014-01-15	2019-06-18	Shin Nippon Biomedical Laboratories, Ltd.	Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
JPWO2015108048A1 (ja)	2014-01-15	2017-03-23	株式会社新日本科学	抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
JPWO2015108047A1 (ja)	2014-01-15	2017-03-23	株式会社新日本科学	免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
BR112016016400A2 (pt) *	2014-01-16	2017-10-03	Wave Life Sciences Ltd	Composições de oligonucleotídeos quiralmente controlados, seu uso, sua composição farmacêutica, e métodos
WO2015125845A1 (ja) *	2014-02-20	2015-08-27	塩野義製薬株式会社	含窒素非芳香族複素環を含む核酸のリン酸部位修飾
US10214743B2 (en)	2014-03-04	2019-02-26	Hirofumi Yamamoto	Colorectal cancer drug, and method for predicting prognosis of colorectal cancer patient
WO2015183667A1 (en)	2014-05-28	2015-12-03	The Regents Of The University Of California	HYBRID tRNA/pre-miRNA MOLECULES AND METHODS OF USE
GB201410693D0 (en)	2014-06-16	2014-07-30	Univ Southampton	Splicing modulation
RU2708237C2 (ru)	2014-08-22	2019-12-05	Общество с ограниченной ответственностью "НооГен"	Модифицированные олигонуклеотиды и способ их получения
AU2015327836B2 (en)	2014-10-03	2021-07-01	Cold Spring Harbor Laboratory	Targeted augmentation of nuclear gene output
WO2016079183A1 (en) *	2014-11-19	2016-05-26	Roche Innovation Center Copenhagen A/S	Lna chiral phosphorothioates
US10815481B2 (en)	2014-12-16	2020-10-27	Roche Innovation Center Copenhagen A/S	Chiral library screen
EP3234134B1 (en)	2014-12-17	2020-05-27	ProQR Therapeutics II B.V.	Targeted rna editing
IL320434A (en)	2015-07-22	2025-06-01	Wave Life Sciences Ltd	Oligonucleotide preparations and methods
EP4285912A3 (en)	2015-09-25	2024-07-10	Ionis Pharmaceuticals, Inc.	Compositions and methods for modulating ataxin 3 expression
IL295755A (en) *	2015-10-09	2022-10-01	Wave Life Sciences Ltd	Oligonucleotide compositions and methods thereof
CN108603230A (zh)	2015-10-09	2018-09-28	南安普敦大学	基因表达的调节与蛋白质表达失调的筛选
US11096956B2 (en)	2015-12-14	2021-08-24	Stoke Therapeutics, Inc.	Antisense oligomers and uses thereof
WO2017106377A1 (en)	2015-12-14	2017-06-22	Cold Spring Harbor Laboratory	Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome
EP3409281A4 (en) *	2016-01-28	2019-09-11	Toray Industries, Inc.	PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF CANCER
CN108779132B (zh) *	2016-03-13	2022-04-15	波涛生命科学有限公司	用于亚磷酰胺和寡核苷酸合成的组合物和方法
WO2017157672A1 (en) *	2016-03-18	2017-09-21	Roche Innovation Center Copenhagen A/S	Acyl-protected l-lna-guanosine monomers
WO2017173301A1 (en)	2016-04-01	2017-10-05	Avidity Biosciences Llc	Egfr nucleic acids and uses thereof
US20170283795A1 (en)	2016-04-01	2017-10-05	Avidity Biosciences Llc	Phosphatidylinositol-3-kinase nucleic acids and uses thereof
JP2019513371A (ja)	2016-04-01	2019-05-30	アビディティーバイオサイエンシーズエルエルシー	核酸ポリペプチド組成物とその使用
EP3436585B1 (en)	2016-04-01	2022-07-20	Avidity Biosciences, Inc.	Kras nucleic acids and uses thereof
WO2017173297A1 (en)	2016-04-01	2017-10-05	Avidity Biosciences Llc	Beta-catenin nucleic acids and uses thereof
WO2017184529A1 (en)	2016-04-18	2017-10-26	Sarepta Therapeutics, Inc.	Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene
MX2018013157A (es)	2016-04-29	2019-05-23	Sarepta Therapeutics Inc	Analogos de oligonucleotidos dirigidos a lmna humana.
EP3452596A4 (en)	2016-05-04	2020-03-18	Wave Life Sciences Ltd.	OLIGONUCLEOTIDE COMPOSITIONS AND RELATED METHODS
EP3455232B1 (en) *	2016-05-12	2020-05-06	Roche Innovation Center Copenhagen A/S	Enhanced coupling of stereodefined oxazaphospholidine phosphoramidite monomers to nucleoside or oligonucleotide
EP3458464B1 (en) *	2016-05-18	2026-04-15	ETH Zurich	Stereoselective synthesis of phosphorothioate oligoribonucleotides
JP2019520339A (ja) *	2016-06-03	2019-07-18	ウェイブライフサイエンシズリミテッドＷａｖｅＬｉｆｅＳｃｉｅｎｃｅｓＬｔｄ．	オリゴヌクレオチド、その組成物および方法
EP4219767A1 (en)	2016-06-17	2023-08-02	F. Hoffmann-La Roche AG	Papd5 and papd7 inhibitors for treating a hepatitis b infection
WO2017220751A1 (en)	2016-06-22	2017-12-28	Proqr Therapeutics Ii B.V.	Single-stranded rna-editing oligonucleotides
JP2019525742A (ja)	2016-06-30	2019-09-12	サレプタセラピューティクス，インコーポレイテッド	筋ジストロフィーに対するエクソンスキッピングオリゴマー
CA3033867A1 (en) *	2016-08-17	2018-02-22	Solstice Biologics, Ltd.	Polynucleotide constructs
CN110352244B (zh)	2016-09-01	2023-03-21	ProQR治疗上市公司Ⅱ	化学修饰的编辑rna的单链寡核苷酸
HUE065170T2 (hu) *	2016-09-29	2024-05-28	Biogen Ma Inc	Vegyületek és módszerek a TAU expresszió csökkentésére
JOP20190104A1 (ar) *	2016-11-10	2019-05-07	Ionis Pharmaceuticals Inc	مركبات وطرق لتقليل التعبير عن atxn3
US11873316B2 (en)	2016-11-23	2024-01-16	Wave Life Sciences Ltd.	Compositions and methods for phosphoramidite and oligonucleotide synthesis
CA3043768A1 (en)	2016-11-29	2018-06-07	PureTech Health LLC	Exosomes for delivery of therapeutic agents
KR20240006023A (ko)	2016-12-19	2024-01-12	사렙타 쎄러퓨틱스 인코퍼레이티드	근육 이상증에 대한 엑손 스킵핑 올리고머 결합체
PT3554552T (pt)	2016-12-19	2022-10-03	Sarepta Therapeutics Inc	Conjugados de oligómero de skipping de exão para distrofia muscular
KR102810425B1 (ko)	2016-12-19	2025-05-21	사렙타 쎄러퓨틱스 인코퍼레이티드	근육 이상증에 대한 엑손 스킵핑 올리고머 결합체
MX2019008199A (es)	2017-01-06	2019-11-25	Avidity Biosciences Llc	Composiciones de acido nucleico polipeptido y metodos de induccion de la omision de exon.
EP3571300A1 (en)	2017-01-19	2019-11-27	ProQR Therapeutics II B.V.	Oligonucleotide complexes for use in rna editing
KR20190135494A (ko) *	2017-03-29	2019-12-06	로슈 이노베이션 센터 코펜하겐 에이/에스	입체한정된 포스포로티오에이트 올리고뉴클레오티드의 제조를 위한 직교 보호기
EP3603648B1 (en)	2017-03-29	2025-09-17	Shionogi & Co., Ltd	Complex of nucleic acid medicine and multibranched lipid
CN120330183A (zh) *	2017-06-02	2025-07-18	波涛生命科学有限公司	寡核苷酸组合物及其使用方法
CA3065523A1 (en)	2017-06-02	2018-12-06	Wave Life Sciences Ltd.	Oligonucleotide compositions and methods of use thereof
JP2020522510A (ja)	2017-06-02	2020-07-30	ウェイブライフサイエンシズリミテッドＷａｖｅＬｉｆｅＳｃｉｅｎｃｅｓＬｔｄ．	オリゴヌクレオチド組成物及びその使用方法
US11718638B2 (en)	2017-06-21	2023-08-08	Wave Life Sciences Ltd.	Compounds, compositions and methods for synthesis
WO2019002237A1 (en) *	2017-06-28	2019-01-03	Roche Innovation Center Copenhagen A/S	METHOD OF MULTIPLE COUPLING AND OXIDATION
US11597744B2 (en)	2017-06-30	2023-03-07	Sirius Therapeutics, Inc.	Chiral phosphoramidite auxiliaries and methods of their use
GB201711809D0 (en)	2017-07-21	2017-09-06	Governors Of The Univ Of Alberta	Antisense oligonucleotide
EP3664816A4 (en) *	2017-08-08	2021-05-19	Wave Life Sciences Ltd.	OLIGONUCLEOTIDE COMPOSITIONS AND RELATED PROCESSES
KR102318434B1 (ko)	2017-08-25	2021-11-01	스톡 테라퓨틱스, 인크.	병태 및 질환 치료용 안티센스 올리고머
CA3072110A1 (en) *	2017-09-18	2019-03-21	Wave Life Sciences Ltd.	Technologies for oligonucleotide preparation
EA201991450A1 (ru)	2017-09-22	2019-12-30	Сарепта Терапьютикс, Инк.	Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
WO2019067979A1 (en)	2017-09-28	2019-04-04	Sarepta Therapeutics, Inc.	POLYTHERAPIES FOR TREATING MUSCLE DYSTROPHY
EP3687547A1 (en)	2017-09-28	2020-08-05	Sarepta Therapeutics, Inc.	Combination therapies for treating muscular dystrophy
WO2019067981A1 (en)	2017-09-28	2019-04-04	Sarepta Therapeutics, Inc.	POLYTHERAPIES FOR TREATING MUSCLE DYSTROPHY
EP3691657A4 (en)	2017-10-04	2021-07-21	Avidity Biosciences, Inc.	NUCLEIC ACID POLYPEPTIDE COMPOSITIONS AND USES THEREOF
EP3694530A4 (en)	2017-10-12	2021-06-30	Wave Life Sciences Ltd.	COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES
CN111511914B (zh)	2017-10-16	2023-11-17	豪夫迈·罗氏有限公司	减少PAPD5和PAPD7 mRNA的核酸分子用于治疗乙型肝炎感染
US11555189B2 (en)	2017-10-18	2023-01-17	Sarepta Therapeutics, Inc.	Antisense oligomer compounds
TWI809004B (zh) *	2017-11-09	2023-07-21	美商Ionis製藥公司	用於降低snca表現之化合物及方法
CN111527206A (zh) *	2017-11-13	2020-08-11	赛伦斯治疗有限责任公司	用于抑制靶标基因表达的包含二硫代磷酸酯键的核酸
KR102723989B1 (ko)	2017-12-01	2024-11-01	더 텍사스 에이 & 엠 유니버시티 시스템	엔젤만 증후군 안티센스 치료
AU2018378812B2 (en)	2017-12-06	2025-05-22	Avidity Biosciences, Inc.	Compositions and methods of treating muscle atrophy and myotonic dystrophy
EP3728281A1 (en) *	2017-12-21	2020-10-28	Alnylam Pharmaceuticals Inc.	Chirally-enriched double-stranded rna agents
CN108186564B (zh) *	2018-01-03	2020-06-02	上海市肿瘤研究所	一种肿瘤微环境响应型基因纳米胶束及其制备方法和应用
US12203068B2 (en)	2018-02-04	2025-01-21	The Texas A&M University System	Heterochiral nucleic acid strand-displacement systems and methods
IL277066B2 (en) *	2018-03-14	2023-09-01	Hoffmann La Roche	History of lna-dicarboxylic acid and process for their preparation
SG11202009877XA (en) *	2018-04-12	2020-11-27	Wave Life Sciences Ltd	Oligonucleotide compositions and methods of use thereof
CA3099280A1 (en)	2018-05-04	2019-11-07	Stoke Therapeutics, Inc.	Methods and compositions for treatment of cholesteryl ester storage disease
MX2020011570A (es)	2018-05-07	2020-11-24	Alnylam Pharmaceuticals Inc	Administracion extrahepatica.
EP4663758A3 (en)	2018-05-09	2026-04-29	Ionis Pharmaceuticals, Inc.	Compounds and methods for reducing atxn3 expression
US12391942B2 (en)	2018-05-11	2025-08-19	Wave Life Sciences Ltd.	Oligonucleotide compositions and methods of use thereof
GB201808146D0 (en)	2018-05-18	2018-07-11	Proqr Therapeutics Ii Bv	Stereospecific Linkages in RNA Editing Oligonucleotides
US10758629B2 (en)	2018-05-29	2020-09-01	Sarepta Therapeutics, Inc.	Exon skipping oligomer conjugates for muscular dystrophy
EP3806868A4 (en)	2018-06-13	2022-06-22	Sarepta Therapeutics, Inc.	EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY
PE20210346A1 (es)	2018-07-03	2021-02-25	Hoffmann La Roche	Oligonucleotidos para modular la expresion de tau
TW202449155A (zh)	2018-07-27	2024-12-16	美商薩羅塔治療公司	用於肌肉萎縮症之外顯子跳躍寡聚物
US20230041178A1 (en) *	2018-12-03	2023-02-09	Triplet Therapeutics, Inc.	Methods for the treatment of trinucleotide repeat exapnsion disorders associated with ogg1 activity
JP2022513719A (ja) *	2018-12-06	2022-02-09	ウェイブライフサイエンシズリミテッド	オリゴヌクレオチド組成物及びその方法
IL318474A (en)	2018-12-13	2025-03-01	Sarepta Therapeutics Inc	Axon-skipping oligomer complexes for muscular dystrophy
IL312067B2 (en)	2018-12-21	2025-08-01	Avidity Biosciences Inc	Anti-transferrin receptor antibodies and uses thereof
CN109837326B (zh) *	2019-01-17	2022-07-05	嘉兴学院	基于多价捕获并放大输出信号的生物靶标分子检测方法
TWI845623B (zh) *	2019-02-27	2024-06-21	日商日產化學股份有限公司	樹脂組成物、樹脂膜及液晶顯示元件
AU2020227825B2 (en)	2019-02-27	2026-03-26	Stoke Therapeutics, Inc.	Antisense oligomers for treatment of conditions and diseases
JP2022525541A (ja) *	2019-03-20	2022-05-17	ウェイブライフサイエンシズリミテッド	オリゴヌクレオチド調製に有用な技術
CA3134683A1 (en) *	2019-03-26	2020-10-01	Rutgers, The State University Of New Jersey	Compositions and methods for treating neurodegenerative disorders
WO2020214763A1 (en)	2019-04-18	2020-10-22	Sarepta Therapeutics, Inc.	Compositions for treating muscular dystrophy
WO2020219820A1 (en)	2019-04-25	2020-10-29	Avidity Biosciences, Inc.	Nucleic acid compositions and methods of multi-exon skipping
WO2020236618A1 (en) *	2019-05-17	2020-11-26	Ionis Pharmaceuticals, Inc.	Synthesis of oligomeric compounds comprising phosphorothioate diester and phosphate diester linkages
CN110346493B (zh) *	2019-05-23	2021-01-05	中国人民解放军军事科学院军事医学研究院	检测猕猴血浆中中期因子反义寡核苷酸含量的方法
US12006499B2 (en)	2019-06-06	2024-06-11	Avidity Biosciences, Inc.	Una amidites and uses thereof
CN114375296A (zh)	2019-06-06	2022-04-19	艾维迪提生物科学公司	核酸多肽组合物及其用途
WO2021154941A1 (en) *	2020-01-31	2021-08-05	Alnylam Pharmaceuticals, Inc.	Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
EP4110919A4 (en) *	2020-02-28	2024-06-05	Ionis Pharmaceuticals, Inc.	COMPOUNDS AND METHODS FOR MODULATING SCN1A EXPRESSION
WO2021188390A1 (en)	2020-03-19	2021-09-23	Avidity Biosciences, Inc.	Compositions and methods of treating facioscapulohumeral muscular dystrophy
SI4126066T1 (sl)	2020-03-27	2026-04-30	Avidity Biosciences, Inc.	Sestavki in postopki zdravljenja mišične distrofije
KR20230023612A (ko) *	2020-04-02	2023-02-17	마이레큘, 인크.	조작된 올리고뉴클레오티드를 사용한 표적화된 억제
US20230322842A1 (en) *	2020-04-14	2023-10-12	Sumitomo Chemical Company, Limited	Composition containing nucleic acid oligomer
CN115867657A (zh)	2020-05-11	2023-03-28	斯托克制药公司	用于治疗疾患和疾病的opa1反义寡聚物
MX2022014606A (es) *	2020-05-22	2023-03-08	Wave Life Sciences Ltd	Composiciones de oligonucleótidos bicatenarios y métodos relacionados con las mismas.
CN112063608B (zh) *	2020-08-27	2022-06-17	浙江工业大学	一种脂肪酸光脱羧酶突变体及其在l-草铵膦合成中的应用
CN118265544A (zh)	2021-09-16	2024-06-28	艾维迪提生物科学公司	治疗面肩肱型肌营养不良的组合物和方法
WO2023055774A1 (en)	2021-09-30	2023-04-06	Sarepta Therapeutics, Inc.	Antisense oligonucleotides having one or more abasic units
CN114230498B (zh) *	2021-12-30	2023-11-17	湖北华世通生物医药科技有限公司	β-(二甲氨基)乙基对甲苯磺酸巯酯盐酸盐的制备方法
CN115181736B (zh) *	2022-01-07	2023-05-30	中国科学院海洋研究所	一种可以结合脂多糖的蛋白酶pck及其制备和应用
EP4479535A1 (en)	2022-02-14	2024-12-25	ProQR Therapeutics II B.V.	Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia
US12071621B2 (en)	2022-04-05	2024-08-27	Avidity Biosciences, Inc.	Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping
JP2025524566A (ja)	2022-07-15	2025-07-30	プロキューアールセラピューティクスツーベスローテンフェンノートシャップ	Ａｄａｒ媒介ｒｎａ編集のためのオリゴヌクレオチドおよびその使用
US20260027237A1 (en)	2022-07-15	2026-01-29	Proqr Therapeutics Ii B.V.	Chemically modified oligonucleotides for adar-mediated rna editing
JP2025533454A (ja)	2022-09-21	2025-10-07	サレプタセラピューティクス，インコーポレイテッド	Ｄｍｄアンチセンスオリゴヌクレオチド介在性エクソンスキッピング効率
GB202215614D0 (en)	2022-10-21	2022-12-07	Proqr Therapeutics Ii Bv	Heteroduplex rna editing oligonucleotide complexes
WO2024097310A2 (en) *	2022-11-01	2024-05-10	Impilo Therapeutics, Inc.	Targeted non-charged-nucleic acid (ncna) delivery and related tumor penetrating nanocomplexes
WO2024110565A1 (en)	2022-11-24	2024-05-30	Proqr Therapeutics Ii B.V.	Antisense oligonucleotides for the treatment of hereditary hfe-hemochromatosis
GB202218090D0 (en)	2022-12-01	2023-01-18	Proqr Therapeutics Ii Bv	Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency
AU2023390632A1 (en)	2022-12-09	2025-07-10	Proqr Therapeutics Ii B.V.	Antisense oligonucleotides for the treatment of cardiovascular disease
GB202300865D0 (en)	2023-01-20	2023-03-08	Proqr Therapeutics Ii Bv	Delivery of oligonucleotides
WO2024175550A1 (en)	2023-02-20	2024-08-29	Proqr Therapeutics Ii B.V.	Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease
KR102767906B1 (ko) *	2023-03-06	2025-02-19	주식회사 아이씨바이오	친환경 추출공법을 이용하여 식물 유래 핵산을 제조하는 방법
GB202304363D0 (en)	2023-03-24	2023-05-10	Proqr Therapeutics Ii Bv	Chemically modified antisense oligonucleotides for use in RNA editing
EP4689110A1 (en)	2023-03-24	2026-02-11	ProQR Therapeutics II B.V.	Antisense oligonucleotides for the treatment of neurological disorders
EP4688143A1 (en)	2023-03-27	2026-02-11	ProQR Therapeutics II B.V.	Antisense oligonucleotides for the treatment of liver disease
TW202442246A (zh)	2023-04-27	2024-11-01	美商薩羅塔治療公司	用於治療慢性腎病之反義寡聚物
TW202516003A (zh)	2023-06-16	2025-04-16	荷蘭商Ｐｒｏｑｒ治療上市公司Ｉｉ	用於治療神經退化性疾病之反義寡核苷酸
EP4735602A2 (en)	2023-06-27	2026-05-06	Atrium Therapeutics, Inc.	Compositions and methods of using prkag2-targeting antibody-oligonucleotide conjugates abstract
AU2024308906A1 (en)	2023-06-30	2026-02-05	Atrium Therapeutics, Inc.	Compositions and methods of using pln-targeting antibody-oligonucleotide conjugates
WO2025015335A1 (en)	2023-07-13	2025-01-16	Korro Bio, Inc.	Rna-editing oligonucleotides and uses thereof
WO2025051946A1 (en)	2023-09-07	2025-03-13	Proqr Therapeutics Ii B.V.	Antisense oligonucleotides for the treatment of metabolic disorders
WO2025064469A1 (en)	2023-09-18	2025-03-27	Omega Therapeutics, Inc.	Methods for assessing dosage for epigenetic modifying agents
WO2025085810A2 (en)	2023-10-18	2025-04-24	Sarepta Therapeutics, Inc.	Antisense oligomers for treatment of centronuclear myopathies
WO2025096809A1 (en)	2023-10-31	2025-05-08	Korro Bio, Inc.	Oligonucleotides comprising phosphoramidate internucleotide linkages
CN117204605B (zh) *	2023-11-02	2025-11-18	云南中烟工业有限责任公司	一种加热卷烟香味物质温控释放结构
WO2025104239A1 (en)	2023-11-16	2025-05-22	Proqr Therapeutics Ii B.V.	Antisense oligonucleotides for the treatment of classic galactosemia
WO2025128799A1 (en)	2023-12-12	2025-06-19	Korro Bio, Inc.	Double-stranded rna-editing oligonucleotides and uses thereof
WO2025132708A1 (en)	2023-12-20	2025-06-26	Proqr Therapeutics Ii B.V.	Antisense oligonucleotides for the treatment of huntington's disease
GB202404661D0 (en)	2024-04-02	2024-05-15	Proqr Therapeutics Ii Bv	Antisense oligoncleotides for the treatment of liver disease
WO2025224230A1 (en)	2024-04-25	2025-10-30	Proqr Therapeutics Ii B.V.	Antisense oligonucleotides for the treatment of fatty liver disease
GB202410081D0 (en)	2024-07-11	2024-08-28	Proqr Therapeutics Ii Bv	Antisense oligonucleotides for the treatment of cardiovascular disease
WO2026022136A1 (en)	2024-07-23	2026-01-29	Proqr Therapeutics Ii B.V.	Antisense oligonucleotides for the treatment of metabolic disorders
WO2026050243A1 (en)	2024-08-26	2026-03-05	Korro Bio, Inc.	Galnac conjugated oligonucleotides for rna editing
WO2026060374A2 (en)	2024-09-16	2026-03-19	Proqr Therapeutics Ii B.V.	Antisense oligonucleotides for the treatment of neurological disorders
WO2026068781A1 (en)	2024-09-30	2026-04-02	Proqr Therapeutics Ii B.V.	Antisense oligonucleotides for the treatment of liver disease

Family Cites Families (650)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2878264A (en)		1959-03-17		Substituted amino alcohols
DE133885C (da)
US513030A (en)		1894-01-16		Machine for waxing or coating paper
DE1144279B (de)	1957-09-26	1963-02-28	Robins Co Inc A H	Verfahren zur Herstellung von 3-Aryl-3-hydroxypyrrolidinen und deren Salzen
US3135766A (en)	1961-10-03	1964-06-02	Mead Johnson & Co	3-substituted-3-pyrrolidinols
US3484473A (en)	1967-05-12	1969-12-16	Buckman Labor Inc	Methylene bisesters of thiolsulfonic acids
DE1934150A1 (de)	1968-07-10	1970-01-15	Pennwalt Corp	Neue 1-Alkanoyloxy-1,2,4,5-tetrahydro-3H,3-benzazepine
US3687808A (en)	1969-08-14	1972-08-29	Univ Leland Stanford Junior	Synthetic polynucleotides
US3745162A (en)	1970-08-31	1973-07-10	Robins Co Inc A H	1,2,3,4-tetrahydroisoquinoline-2-(thio)-carboxamides
GB1448437A (en)	1973-02-24	1976-09-08	Beecham Group Ltd	Diphenylpropylamines
US4022791A (en)	1975-06-03	1977-05-10	Pfizer Inc.	2-Aminomethyl-3,4-dihydronaphthalenes
GB1504424A (en)	1975-08-09	1978-03-22	Beecham Group Ltd	Isoquinoline-derived aminoethers
BR7807288A (pt)	1977-11-08	1979-06-12	Genentech Inc	Processo para sintese de polinucleotidos
DD133885B1 (de)	1978-01-04	1981-02-25	Hans Lehmann	Mittel zur bekaempfung von phytopathogenen bakterien und pilzen
US4500707A (en)	1980-02-29	1985-02-19	University Patents, Inc.	Nucleosides useful in the preparation of polynucleotides
US5132418A (en)	1980-02-29	1992-07-21	University Patents, Inc.	Process for preparing polynucleotides
US4458066A (en)	1980-02-29	1984-07-03	University Patents, Inc.	Process for preparing polynucleotides
US4415732A (en)	1981-03-27	1983-11-15	University Patents, Inc.	Phosphoramidite compounds and processes
US4668777A (en)	1981-03-27	1987-05-26	University Patents, Inc.	Phosphoramidite nucleoside compounds
US4973679A (en)	1981-03-27	1990-11-27	University Patents, Inc.	Process for oligonucleo tide synthesis using phosphormidite intermediates
US4542142A (en)	1982-11-22	1985-09-17	Roussel Uclaf	Insecticidal cyclopropane carboxylic acid derivatives with 3-unsaturated-side chain
USRE34069E (en)	1983-08-18	1992-09-15	Biosyntech Gmbh	Process for the preparation of oligonucleotides
DE3329892A1 (de)	1983-08-18	1985-03-07	Köster, Hubert, Prof. Dr., 2000 Hamburg	Verfahren zur herstellung von oligonucleotiden
US5118800A (en)	1983-12-20	1992-06-02	California Institute Of Technology	Oligonucleotides possessing a primary amino group in the terminal nucleotide
US5643889A (en)	1984-07-11	1997-07-01	Temple University-Of The Commonwealth System Of Pennsylvania	Cholesterol conjugates of 2'5'-oligoadenylate derivatives and antiviral uses thereof
FR2567892B1 (fr)	1984-07-19	1989-02-17	Centre Nat Rech Scient	Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons
US5367066A (en)	1984-10-16	1994-11-22	Chiron Corporation	Oligonucleotides with selectably cleavable and/or abasic sites
FR2575751B1 (fr)	1985-01-08	1987-04-03	Pasteur Institut	Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques
FR2576898B1 (fr)	1985-02-01	1988-01-08	Lafon Labor	Derives de 3-phenyl-tetrahydropyridine, procede de preparation et utilisation en therapeutique
US4659774A (en)	1985-11-01	1987-04-21	American Hoechst Corporation	Support for solid-phase oligonucleotide synthesis
US4735949A (en)	1986-02-18	1988-04-05	Warner-Lambert Company	Disubstituted-7-pyrrolidinonaphthyridine antibacterial agents
US4840956A (en)	1986-02-18	1989-06-20	Warner-Lambert Company	Novel disubstituted-7-pyrrolidinoquinoline antibacterial agents
IL83663A0 (en)	1986-10-27	1988-01-31	Robins Co Inc A H	Preparation of 3-pyrrolidinols
EP0366685B1 (en)	1987-06-24	1994-10-19	Howard Florey Institute Of Experimental Physiology And Medicine	Nucleoside derivatives
DE3884517T2 (de)	1987-07-30	1994-02-10	Kupat Holim Health Insurance	Biologisch aktive Carbonsäureester.
US4923901A (en)	1987-09-04	1990-05-08	Millipore Corporation	Membranes with bound oligonucleotides and peptides
US5175273A (en)	1988-07-01	1992-12-29	Genentech, Inc.	Nucleic acid intercalating agents
US5047524A (en)	1988-12-21	1991-09-10	Applied Biosystems, Inc.	Automated system for polynucleotide synthesis and purification
US5262530A (en)	1988-12-21	1993-11-16	Applied Biosystems, Inc.	Automated system for polynucleotide synthesis and purification
JP2794461B2 (ja)	1989-08-17	1998-09-03	有機合成薬品工業株式会社	ホスホアミダイト化合物及びそれを用いたオリゴリボヌクレオチドの固相合成法
US5141813A (en)	1989-08-28	1992-08-25	Clontech Laboratories, Inc.	Multifunctional controlled pore glass reagent for solid phase oligonucleotide synthesis
US5134066A (en)	1989-08-29	1992-07-28	Monsanto Company	Improved probes using nucleosides containing 3-dezauracil analogs
CA2029273A1 (en)	1989-12-04	1991-06-05	Christine L. Brakel	Modified nucleotide compounds
US5130302A (en)	1989-12-20	1992-07-14	Boron Bilogicals, Inc.	Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
CA2071897A1 (en)	1989-12-28	1991-06-29	Richard A. Glennon	Sigma receptor ligands and the use thereof
US5914396A (en)	1990-01-11	1999-06-22	Isis Pharmaceuticals, Inc.	2'-O-modified nucleosides and phosphoramidites
US5457191A (en)	1990-01-11	1995-10-10	Isis Pharmaceuticals, Inc.	3-deazapurines
US5506212A (en)	1990-01-11	1996-04-09	Isis Pharmaceuticals, Inc.	Oligonucleotides with substantially chirally pure phosphorothioate linkages
US5587361A (en)	1991-10-15	1996-12-24	Isis Pharmaceuticals, Inc.	Oligonucleotides having phosphorothioate linkages of high chiral purity
US5212295A (en)	1990-01-11	1993-05-18	Isis Pharmaceuticals	Monomers for preparation of oligonucleotides having chiral phosphorus linkages
US5852188A (en)	1990-01-11	1998-12-22	Isis Pharmaceuticals, Inc.	Oligonucleotides having chiral phosphorus linkages
US5459255A (en)	1990-01-11	1995-10-17	Isis Pharmaceuticals, Inc.	N-2 substituted purines
US5635488A (en)	1991-10-15	1997-06-03	Isis Pharmaceuticals, Inc.	Compounds having phosphorodithioate linkages of high chiral purity
KR927003044A (ko)	1990-01-11	1992-12-17	크리스토퍼 케이. 미라벨리	Rna 활성과 유전자 발현을 검출하고 조절하는 조성물 및 그 방법
US7101993B1 (en)	1990-01-11	2006-09-05	Isis Pharmaceuticals, Inc.	Oligonucleotides containing 2′-O-modified purines
US5620963A (en)	1991-10-15	1997-04-15	Isis Pharmaceuticals, Inc.	Oligonucleotides for modulating protein kinase C having phosphorothioate linkages of high chiral purity
US5646265A (en)	1990-01-11	1997-07-08	Isis Pharmceuticals, Inc.	Process for the preparation of 2'-O-alkyl purine phosphoramidites
US6339066B1 (en)	1990-01-11	2002-01-15	Isis Pharmaceuticals, Inc.	Antisense oligonucleotides which have phosphorothioate linkages of high chiral purity and which modulate βI, βII, γ, δ, Ε, ζ and η isoforms of human protein kinase C
US5681941A (en)	1990-01-11	1997-10-28	Isis Pharmaceuticals, Inc.	Substituted purines and oligonucleotide cross-linking
US5587470A (en)	1990-01-11	1996-12-24	Isis Pharmaceuticals, Inc.	3-deazapurines
US5292875A (en)	1990-04-20	1994-03-08	Lynx Therapeutics, Inc.	Method of synthesizing sulfurized oligonucleotide analogs
US5151510A (en)	1990-04-20	1992-09-29	Applied Biosystems, Inc.	Method of synethesizing sulfurized oligonucleotide analogs
HUT63568A (en)	1990-05-23	1993-09-28	Isis Pharmaceuticals Inc	Composition and process for controlling the activity of rna by modifying the rna 5' cap structure
US5861254A (en)	1997-01-31	1999-01-19	Nexstar Pharmaceuticals, Inc.	Flow cell SELEX
US5527894A (en)	1990-06-11	1996-06-18	Nexstar Pharmacueticals, Inc.	Ligands of HIV-1 tat protein
US6261774B1 (en)	1990-06-11	2001-07-17	Gilead Sciences, Inc.	Truncation selex method
US5869641A (en)	1990-06-11	1999-02-09	Nexstar Pharmaceuticals, Inc.	High affinity nucleic acid ligands of CD4
ES2259800T3 (es)	1990-06-11	2006-10-16	Gilead Sciences, Inc.	Procedimientos de uso de ligandos de acido nucleico.
US6001577A (en)	1998-06-08	1999-12-14	Nexstar Pharmaceuticals, Inc.	Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5654151A (en)	1990-06-11	1997-08-05	Nexstar Pharmaceuticals, Inc.	High affinity HIV Nucleocapsid nucleic acid ligands
US6331394B1 (en)	1991-06-10	2001-12-18	Gilead Sciences, Inc.	Nucleic acid ligands to integrins
US5580737A (en)	1990-06-11	1996-12-03	Nexstar Pharmaceuticals, Inc.	High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US5496938A (en)	1990-06-11	1996-03-05	Nexstar Pharmaceuticals, Inc.	Nucleic acid ligands to HIV-RT and HIV-1 rev
US5705337A (en)	1990-06-11	1998-01-06	Nexstar Pharmaceuticals, Inc.	Systematic evolution of ligands by exponential enrichment: chemi-SELEX
US5503978A (en)	1990-06-11	1996-04-02	University Research Corporation	Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase
US5543293A (en)	1990-06-11	1996-08-06	Nexstar Pharmaceuticals, Inc.	DNA ligands of thrombin
US5726017A (en)	1990-06-11	1998-03-10	Nexstar Pharmaceuticals, Inc.	High affinity HIV-1 gag nucleic acid ligands
US5780228A (en)	1990-06-11	1998-07-14	Nexstar Pharmaceuticals, Inc.	High affinity nucleic acid ligands to lectins
US5668264A (en)	1990-06-11	1997-09-16	Nexstar Pharmaceuticals, Inc.	High affinity PDGF nucleic acid ligands
US5846713A (en)	1990-06-11	1998-12-08	Nexstar Pharmaceuticals, Inc.	High affinity HKGF nucleic acid ligands and inhibitors
US5683867A (en)	1990-06-11	1997-11-04	Nexstar Pharmaceuticals, Inc.	Systematic evolution of ligands by exponential enrichment: blended SELEX
US5587468A (en)	1990-06-11	1996-12-24	University Research Corporation	High affinity nucleic acid ligands to HIV integrase
US6232071B1 (en)	1990-06-11	2001-05-15	Gilead Sciences, Inc.	Tenascin-C nucleic acid ligands
US5637459A (en)	1990-06-11	1997-06-10	Nexstar Pharmaceuticals, Inc.	Systematic evolution of ligands by exponential enrichment: chimeric selex
US5567588A (en)	1990-06-11	1996-10-22	University Research Corporation	Systematic evolution of ligands by exponential enrichment: Solution SELEX
US5610289A (en)	1990-07-27	1997-03-11	Isis Pharmaceuticals, Inc.	Backbone modified oligonucleotide analogues
JPH0874B2 (ja)	1990-07-27	1996-01-10	アイシス・ファーマシューティカルス・インコーポレーテッド	遺伝子発現を検出および変調するヌクレアーゼ耐性、ピリミジン修飾オリゴヌクレオチド
US5432272A (en)	1990-10-09	1995-07-11	Benner; Steven A.	Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
US5512668A (en)	1991-03-06	1996-04-30	Polish Academy Of Sciences	Solid phase oligonucleotide synthesis using phospholane intermediates
US7015315B1 (en)	1991-12-24	2006-03-21	Isis Pharmaceuticals, Inc.	Gapped oligonucleotides
US6414112B1 (en)	1991-05-24	2002-07-02	Ole Buchardt	Peptide nucleic acids having 2,6-diaminopurine nucleobases
AT405053B (de)	1991-06-10	1999-05-25	Lucky Ltd	Hepatitis-c-diagnosemittel und -impfstoffe
US5646267A (en)	1991-08-05	1997-07-08	Polish Academy Of Sciences	Method of making oligonucleotides and oligonucleotide analogs using phospholanes and enantiomerically resolved phospholane analogues
US5359052A (en)	1991-08-05	1994-10-25	Polish Academy Of Sciences	Chalcophospholanes useful in the synthesis of oligonucleoside phosphorothioates, phosphorodithioates and related selenates
US7119184B2 (en)	1991-08-12	2006-10-10	Isis Pharmaceuticals, Inc.	Oligonucleotides having A-DNA form and B-DNA form conformational geometry
US6369209B1 (en)	1999-05-03	2002-04-09	Isis Pharmaceuticals, Inc.	Oligonucleotides having A-DNA form and B-DNA form conformational geometry
DE69232699T2 (de)	1991-10-15	2003-02-06	Isis Pharmaceutical, Inc.	Über chirale phosphoratome gebundene oligonukleotide
US5576302A (en)	1991-10-15	1996-11-19	Isis Pharmaceuticals, Inc.	Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity
US5654284A (en)	1991-10-15	1997-08-05	Isis Pharmaceuticals, Inc.	Oligonucleotides for modulating RAF kinase having phosphorothioate linkages of high chiral purity
US5661134A (en)	1991-10-15	1997-08-26	Isis Pharmaceuticals, Inc.	Oligonucleotides for modulating Ha-ras or Ki-ras having phosphorothioate linkages of high chiral purity
US5607923A (en)	1991-10-15	1997-03-04	Isis Pharmaceuticals, Inc.	Oligonucleotides for modulating cytomegalovirus having phosphorothioate linkages of high chiral purity
US5599797A (en)	1991-10-15	1997-02-04	Isis Pharmaceuticals, Inc.	Oligonucleotides having phosphorothioate linkages of high chiral purity
EP0538194B1 (de)	1991-10-17	1997-06-04	Novartis AG	Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte
US5594121A (en)	1991-11-07	1997-01-14	Gilead Sciences, Inc.	Enhanced triple-helix and double-helix formation with oligomers containing modified purines
US5484908A (en)	1991-11-26	1996-01-16	Gilead Sciences, Inc.	Oligonucleotides containing 5-propynyl pyrimidines
US6235887B1 (en)	1991-11-26	2001-05-22	Isis Pharmaceuticals, Inc.	Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
US5359044A (en)	1991-12-13	1994-10-25	Isis Pharmaceuticals	Cyclobutyl oligonucleotide surrogates
JP3131222B2 (ja)	1991-12-24	2001-01-31	アイシス・ファーマシューティカルス・インコーポレーテッド	ギャップを有する２′修飾オリゴヌクレオチド
EP0642589A4 (en)	1992-05-11	1997-05-21	Ribozyme Pharm Inc	METHOD AND REAGENT TO INHIBIT VIRAL REPLICATION.
GB9213601D0 (en)	1992-06-26	1992-08-12	Mastico Robert A	Protein based delivery system
EP0786522A2 (en)	1992-07-17	1997-07-30	Ribozyme Pharmaceuticals, Inc.	Enzymatic RNA molecules for treatment of stenotic conditions
US7067497B2 (en)	1992-09-29	2006-06-27	Isis Pharmaceuticals, Inc.	Modulation of telomere length by oligonucleotides having a G-core sequence
ATE138384T1 (de)	1993-01-25	1996-06-15	Hybridon Inc	Olionukleotidalkylphosphonate und - phosphonothioate
WO1994022890A1 (en)	1993-03-31	1994-10-13	Sterling Winthop Inc.	Novel 5'-substituted nucleosides and oligomers produced therefrom
US5955591A (en) *	1993-05-12	1999-09-21	Imbach; Jean-Louis	Phosphotriester oligonucleotides, amidites and method of preparation
US6015886A (en)	1993-05-24	2000-01-18	Chemgenes Corporation	Oligonucleotide phosphate esters
DE69412704T2 (de)	1993-06-10	1999-02-04	Idemitsu Petrochemical Co., Ltd., Tokio/Tokyo	Spritzgiessform
US5502177A (en)	1993-09-17	1996-03-26	Gilead Sciences, Inc.	Pyrimidine derivatives for labeled binding partners
PT732929E (pt)	1993-10-29	2008-08-26	Brigham & Womens Hospital	Utilização terapêutica de ''engodos'' de elementos cis in vivo
US5643989A (en)	1993-10-29	1997-07-01	Azdel, Inc.	Fiber reinforced functionalized polyolefin composites
US5457187A (en)	1993-12-08	1995-10-10	Board Of Regents University Of Nebraska	Oligonucleotides containing 5-fluorouracil
DE4435728A1 (de)	1994-01-19	1995-07-20	Boehringer Mannheim Gmbh	Biotinsilan-Verbindungen und diese Verbindungen enthaltende Bindematrix
AU1838295A (en)	1994-02-10	1995-08-29	Nexagen, Inc.	High-affinity ligands of basic fibroblast growth factor and thrombin
US6117679A (en)	1994-02-17	2000-09-12	Maxygen, Inc.	Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
DE69527835T2 (de)	1994-02-22	2003-04-10	Novozymes A/S, Bagsvaerd	Methode zur herstellung einer variante eines lipolytischen enzymes
US5596091A (en)	1994-03-18	1997-01-21	The Regents Of The University Of California	Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
BR9507678A (pt)	1994-05-11	1997-09-23	Novo Nordisk As	Construção de dna vetor de expressão recombinante célula proceso para produzir uma enzima enzima preparação de enzima uso da enzima e cultura
US5525711A (en)	1994-05-18	1996-06-11	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Pteridine nucleotide analogs as fluorescent DNA probes
EP1167379A3 (en)	1994-07-15	2004-09-08	University Of Iowa Research Foundation	Immunomodulatory oligonucleotides
US6239116B1 (en)	1994-07-15	2001-05-29	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6207646B1 (en)	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
AU3675195A (en)	1994-09-07	1996-03-27	Hybridon, Inc.	Oligonucleotide prodrugs
US5681940A (en)	1994-11-02	1997-10-28	Icn Pharmaceuticals	Sugar modified nucleosides and oligonucleotides
CN1175281A (zh)	1994-12-22	1998-03-04	海布里登公司	立体特异性硫代磷酸寡核苷酸的合成
GB9501465D0 (en)	1995-01-25	1995-03-15	King S College London	Nucleoside phosphorothioate derivatives,synthesis and use thereof
US6166197A (en)	1995-03-06	2000-12-26	Isis Pharmaceuticals, Inc.	Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
WO1996027606A1 (en)	1995-03-06	1996-09-12	Isis Pharmaceuticals, Inc.	Improved process for the synthesis of 2'-o-substituted pyrimidines and oligomeric compounds therefrom
WO1996027604A1 (en)	1995-03-06	1996-09-12	Nexstar Pharmaceuticals, Inc.	High-affinity oligonucleotide ligands to secretory phospholipase a2(spla2)
DE69638104D1 (de)	1995-04-27	2010-02-11	Takara Bio Inc	Für Lacto-N-biosidase kodierendes Gen
ATE271128T1 (de)	1995-05-11	2004-07-15	Applied Research Systems	Inhibitoren der il-6 aktivitaet
AU5871196A (en)	1995-05-23	1996-12-24	Hybridon, Inc.	Methods and compounds for the synthesis of oligonucleotides and the oligonucleotides thereby produced
WO1996037504A1 (en)	1995-05-23	1996-11-28	Hybridon, Inc.	Novel synthons for stereoselective oligonucleotide synthesis
AU698739B2 (en)	1995-06-06	1998-11-05	Isis Pharmaceuticals, Inc.	Oligonucleotides having phosphorothioate linkages of high chiral purity
US5932450A (en)	1995-06-07	1999-08-03	Gen-Probe Incorporated	Enzymatic synthesis of oligonucleotides using digestible templates
US6699843B2 (en)	1995-06-07	2004-03-02	Gilead Sciences, Inc.	Method for treatment of tumors using nucleic acid ligands to PDGF
US6111095A (en)	1995-06-07	2000-08-29	Merck & Co., Inc.	Capped synthetic RNA, analogs, and aptamers
DE69635849T2 (de)	1995-06-29	2006-10-19	Takara Bio Inc., Otsu	Für Endoglycoceramidase kodierendes Gen
DE69636649T2 (de)	1995-06-29	2007-10-04	Takara Bio Inc., Otsu	Für einen Endoglycoceramidase-Aktivator kodierendes Gen
US6017700A (en) *	1995-08-04	2000-01-25	Bayer Corporation	Cationic oligonucleotides, and related methods of synthesis and use
US5936080A (en)	1996-05-24	1999-08-10	Genta Incorporated	Compositions and methods for the synthesis of organophosphorus derivatives
WO1997009443A1 (en)	1995-09-05	1997-03-13	Michigan State University	PROCESS FOR THE ISOLATION AND PURIFICATION OF TAXOL AND TAXANES FROM TAXUS spp
US5734041A (en)	1995-10-20	1998-03-31	Mcgill University	Preparation of chiral phosphorothioate oligomers
US6476216B1 (en)	1995-10-20	2002-11-05	Mcgill University	Preparation of phosphorothioate oligomers
US6160109A (en)	1995-10-20	2000-12-12	Isis Pharmaceuticals, Inc.	Preparation of phosphorothioate and boranophosphate oligomers
US5856085A (en)	1995-12-01	1999-01-05	The Penn State Research Foundation	Compositions and methods of developing oligonucleotides and oligonucleotide analogs having antiviral activity
US7018793B1 (en)	1995-12-07	2006-03-28	Diversa Corporation	Combinatorial screening of mixed populations of organisms
ATE468396T1 (de)	1996-02-01	2010-06-15	Gilead Sciences Inc	Nukleinsäureliganden mit hoher affinität für das c1q protein des komplementsystems
CN1215994A (zh)	1996-02-15	1999-05-05	国家健康学会	对治疗rsv感染有效的rna酶l激活剂和反义寡核苷酸
US6214805B1 (en)	1996-02-15	2001-04-10	The United States Of America As Represented By The Department Of Health And Human Services	RNase L activators and antisense oligonucleotides effective to treat RSV infections
GB9604669D0 (en)	1996-03-05	1996-05-01	Ciba Geigy Ag	Chemical compounds
US5824669A (en)	1996-03-22	1998-10-20	Nitromed, Inc.	Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
DK0898618T3 (da)	1996-05-10	2008-02-25	Novozymes As	Fremgangsmåde til tilvejebringelse af hidtil ukendte DNA-sekvenser
US5856465A (en)	1996-05-24	1999-01-05	Polska Akademia Nauk Centrum Badan Molekularnych I Makromolekularnych	Compositions and methods for the synthesis of chirally pure organophosphorus nucleoside derivatives
US20080119427A1 (en)	1996-06-06	2008-05-22	Isis Pharmaceuticals, Inc.	Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation
US5898031A (en)	1996-06-06	1999-04-27	Isis Pharmaceuticals, Inc.	Oligoribonucleotides for cleaving RNA
DE19622783A1 (de)	1996-06-07	1997-12-11	Hoechst Ag	Isolierung der Biosynthesegene für Pseudo-Oligosaccharide aus Streptomyces glaucescens GLA.O und ihre Verwendung
JP2000514307A (ja)	1996-07-16	2000-10-31	ジェン―プローブ・インコーポレーテッド	増加した標的特異的ｔ▲下ｍ▼を持つ修飾オリゴヌクレオチドを用いた核酸配列の検出および増幅のための方法
EP0960121B1 (en)	1996-07-24	2005-11-30	BUCHARDT, Dorte	Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
WO1998007734A1 (en)	1996-08-21	1998-02-26	Hybridon, Inc.	Oligonucleotide prodrugs
WO1998008809A1 (en)	1996-08-30	1998-03-05	Hybridon, Inc.	Novel sulfur transfer reagents for oligonucleotide synthesis
US6056973A (en)	1996-10-11	2000-05-02	Sequus Pharmaceuticals, Inc.	Therapeutic liposome composition and method of preparation
US6051698A (en)	1997-06-06	2000-04-18	Janjic; Nebojsa	Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
EP0968226A4 (en)	1996-12-27	2001-02-14	Icn Pharmaceuticals	OLIGOAPTAMERS WITH G-ENRICHED REGIONS AND METHODS FOR MODULATING AN IMMUNE RESPONSE
US6172209B1 (en)	1997-02-14	2001-01-09	Isis Pharmaceuticals Inc.	Aminooxy-modified oligonucleotides and methods for making same
US6639062B2 (en)	1997-02-14	2003-10-28	Isis Pharmaceuticals, Inc.	Aminooxy-modified nucleosidic compounds and oligomeric compounds prepared therefrom
US6369237B1 (en)	1997-03-07	2002-04-09	President And Fellows Of Harvard College	DNA glycosylase inhibitors, and uses related thereto
US6015887A (en)	1997-04-11	2000-01-18	Isis Pharmaceuticals, Inc.	Chiral peptide nucleic acids and methods for preparing same
US6468983B2 (en)	1997-04-21	2002-10-22	The Cleveland Clinic Foundation	RNase L activators and antisense oligonucleotides effective to treat telomerase-expressing malignancies
PL184612B1 (pl)	1997-04-25	2002-11-29	Pan	Sposób wytwarzania modyfikowanych P chiralnych analogów nukleotydów
CA2291839A1 (en)	1997-05-28	1998-12-03	Peter E. Nielsen	Conjugated peptide nucleic acids having enhanced cellular uptake
US6589940B1 (en)	1997-06-06	2003-07-08	Dynavax Technologies Corporation	Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
WO1999005160A2 (en)	1997-07-25	1999-02-04	Hybridon, Inc.	Oligonuclotides having 3' terminal stereospecific phosphorothioates
US6383808B1 (en)	2000-09-11	2002-05-07	Isis Pharmaceuticals, Inc.	Antisense inhibition of clusterin expression
GB9717158D0 (en)	1997-08-13	1997-10-22	King S College London	Solution synthesis of oligonucleotides and their phosphorothioate analogues
US6767739B2 (en)	2001-07-30	2004-07-27	Isis Pharmaceuticals Inc.	Antisense modulation of microsomal triglyceride transfer protein expression
US6750344B1 (en)	1997-09-05	2004-06-15	Isis Pharmaceuticals, Inc.	Amine compounds and combinatorial libraries comprising same
DE19741715A1 (de)	1997-09-22	1999-03-25	Hoechst Ag	Pentopyranosyl-Nucleosid, seine Herstellung und Verwendung
US6528640B1 (en)	1997-11-05	2003-03-04	Ribozyme Pharmaceuticals, Incorporated	Synthetic ribonucleic acids with RNAse activity
US6617438B1 (en)	1997-11-05	2003-09-09	Sirna Therapeutics, Inc.	Oligoribonucleotides with enzymatic activity
US6080543A (en)	1997-12-08	2000-06-27	E. & J. Gallo Winery	Detection of fungal pathogens
US6582936B1 (en)	1997-12-12	2003-06-24	The Regents Of The University Of California	Methods for making nucleic acids
US6248519B1 (en)	1998-03-11	2001-06-19	E & J Gallo Winery	Detection of fermentation-related microorganisms
US7045610B2 (en)	1998-04-03	2006-05-16	Epoch Biosciences, Inc.	Modified oligonucleotides for mismatch discrimination
CA2328602A1 (en)	1998-05-06	1999-11-11	University Of Iowa Research Foundation	Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides
JP2002514397A (ja)	1998-05-14	2002-05-21	コーリーファーマシューティカルゲーエムベーハー	ＣｐＧオリゴヌクレオチドを用いる造血調節の方法
US6867294B1 (en)	1998-07-14	2005-03-15	Isis Pharmaceuticals, Inc.	Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
US6242589B1 (en)	1998-07-14	2001-06-05	Isis Pharmaceuticals, Inc.	Phosphorothioate oligonucleotides having modified internucleoside linkages
JP2002521489A (ja)	1998-07-27	2002-07-16	ユニバーシティオブアイオワリサーチファウンデーション	ＣｐＧオリゴヌクレオチドの立体異性体および関連する方法
PT1104306E (pt)	1998-08-10	2006-05-31	Antigenics Inc	Composicoes de cpg e adjuvantes de saponina e seus metodos
JP3655550B2 (ja)	1998-08-14	2005-06-02	独立行政法人科学技術振興機構	Ｒａｓの標的蛋白質に特異的に結合し得る核酸
WO2000023444A1 (en)	1998-10-21	2000-04-27	Abbott Laboratories	5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
US6995259B1 (en)	1998-10-23	2006-02-07	Sirna Therapeutics, Inc.	Method for the chemical synthesis of oligonucleotides
US6423493B1 (en)	1998-10-26	2002-07-23	Board Of Regents The University Of Texas System	Combinatorial selection of oligonucleotide aptamers
WO2000031110A1 (en)	1998-11-25	2000-06-02	Isis Pharmaceuticals, Inc.	Identification of disease predictive nucleic acids
US6451524B1 (en)	1998-11-25	2002-09-17	Isis Pharmaceuticals, Inc.	Identification of disease predictive nucleic acids
AU2200100A (en)	1998-12-21	2000-07-12	Genencor International, Inc.	Chemically modified enzymes with multiple charged variants
CA2702148C (en)	1999-01-06	2014-03-04	Genenews Inc.	Method of profiling gene expression in a human subject having an infectious disease
US6265172B1 (en)	1999-02-08	2001-07-24	University Of Kentucky	Diagnostic test and therapy for manganese superoxide dismutate (mNsod) associated diseases
US6121437A (en)	1999-03-16	2000-09-19	Isis Pharmaceuticals, Inc.	Phosphate and thiophosphate protecting groups
US6506594B1 (en)	1999-03-19	2003-01-14	Cornell Res Foundation Inc	Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
GB9907245D0 (en)	1999-03-29	1999-05-26	Goldsborough Andrew	Cleavage of nucleic acids from solid supports
JP3072345B1 (ja)	1999-03-31	2000-07-31	農林水産省家畜衛生試験場長	豚丹毒菌の組換えサブユニットワクチン
DE19916417A1 (de)	1999-04-01	2000-10-19	Schering Ag	Amyloidspezifisches Aptamer
JP2002541264A (ja)	1999-04-08	2002-12-03	ユーエイビー・リサーチ・ファウンデーション	冨ｇオリゴヌクレオチドの抗増殖活性およびヌクレオリンに結合するためのその使用方法
US6977245B2 (en)	1999-04-12	2005-12-20	The United States Of America As Represented By The Department Of Health And Human Services	Oligodeoxynucleotide and its use to induce an immune response
US6300069B1 (en)	1999-05-03	2001-10-09	Qiagen Gmbh	Generation and amplification of nucleic acids from ribonucleic acids
US6656730B1 (en)	1999-06-15	2003-12-02	Isis Pharmaceuticals, Inc.	Oligonucleotides conjugated to protein-binding drugs
US6271004B1 (en)	1999-06-25	2001-08-07	Display Systems Biotech A/S	Method for improved reverse transcription at high temperatures
US6066500A (en)	1999-06-25	2000-05-23	Isis Pharmaceuticals Inc.	Antisense modulation of Beta catenin expression
US6569630B1 (en)	1999-07-02	2003-05-27	Conceptual Mindworks, Inc.	Methods and compositions for aptamers against anthrax
US6414135B1 (en)	1999-07-07	2002-07-02	Isis Pharmaceuticals, Inc.	C3′-methylene hydrogen phosphonate monomers and related compounds
US20030092647A1 (en)	2001-08-08	2003-05-15	Crooke Rosanne M.	Antisense modulation of cholesteryl ester transfer protein expression
DE19935756A1 (de)	1999-07-27	2001-02-08	Mologen Forschungs Entwicklung	Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation
US6171795B1 (en)	1999-07-29	2001-01-09	Nexstar Pharmaceuticals, Inc.	Nucleic acid ligands to CD40ligand
US6147200A (en)	1999-08-19	2000-11-14	Isis Pharmaceuticals, Inc.	2'-O-acetamido modified monomers and oligomers
US7264932B2 (en)	1999-09-24	2007-09-04	Applera Corporation	Nuclease inhibitor cocktail
NZ517929A (en)	1999-09-25	2004-02-27	Univ Iowa Res Found	Immunostimulatory nucleic acids
AU783118B2 (en)	1999-09-27	2005-09-29	Coley Pharmaceutical Gmbh	Methods related to immunostimulatory nucleic acid-induced interferon
US6949520B1 (en)	1999-09-27	2005-09-27	Coley Pharmaceutical Group, Inc.	Methods related to immunostimulatory nucleic acid-induced interferon
US20020082227A1 (en)	1999-09-30	2002-06-27	Scott Henry	Use of oligonucleotides for inhibition of complement activation
US6528262B1 (en)	1999-10-06	2003-03-04	Quark Biotech, Inc.	Method for enrichment of natural antisense messenger RNA
JP3463098B2 (ja)	1999-10-08	2003-11-05	独立行政法人産業技術総合研究所	モジュレートアプタマー及びこれを用いた標的タンパク質の検出方法
GB9924285D0 (en)	1999-10-14	1999-12-15	Avecia Ltd	Process
US20010055761A1 (en)	1999-10-29	2001-12-27	Agilent Technologies	Small scale dna synthesis using polymeric solid support with functionalized regions
FR2800750B1 (fr)	1999-11-05	2003-01-31	Centre Nat Rech Scient	Proteines membranaires ctl (choline transporter like) impliquees dans le transport de la choline
AU1656601A (en)	1999-11-12	2001-06-12	Isis Pharmaceuticals, Inc.	Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
US6322985B1 (en)	1999-12-27	2001-11-27	Technion Research And Development Foundation Ltd.	Abundant, well distributed and hyperpolymorphic simple sequence repeats in prokaryote genomes and use of same for prokaryote classification and typing
WO2001050117A1 (en)	1999-12-30	2001-07-12	Cabot Corporation	Sensors with improved properties
US7055094B2 (en)	1999-12-30	2006-05-30	Rutgers, The State University Of New Jersey	Virtual tags and the process of virtual tagging utilizing user feedback in transformation rules
US6649750B1 (en)	2000-01-05	2003-11-18	Isis Pharmaceuticals, Inc.	Process for the preparation of oligonucleotide compounds
US6159697A (en)	2000-01-19	2000-12-12	Isis Pharmaceuticals, Inc.	Antisense modulation of Smad7 expression
US7585847B2 (en)	2000-02-03	2009-09-08	Coley Pharmaceutical Group, Inc.	Immunostimulatory nucleic acids for the treatment of asthma and allergy
GB0004889D0 (en)	2000-03-01	2000-04-19	Avecia Ltd	Synthesis of oligonucleotides
EP1130091A3 (en)	2000-03-01	2001-11-14	Message Pharmaceuticals, Inc.	Bacterial RNaseP Proteins and their use in identifying antibacterial compounds
WO2001070663A2 (en)	2000-03-17	2001-09-27	Corixa Corporation	Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors
ATE274494T1 (de)	2000-04-20	2004-09-15	Hoffmann La Roche	Pyrrolidin und piperidin derivate für die behandlung von neurodegenerativen erkrankungen
DE10019756A1 (de)	2000-04-20	2001-10-25	Bayer Ag	Verfahren zur Herstellung von superabsorbierenden Polymeren aus Polyacrylnitrilen
WO2001085751A1 (en)	2000-05-09	2001-11-15	Reliable Biopharmaceutical, Inc.	Polymeric compounds useful as prodrugs
US6492171B2 (en)	2000-05-16	2002-12-10	Isis Pharmaceuticals, Inc.	Antisense modulation of TERT expression
US6725412B1 (en)	2000-08-15	2004-04-20	Dolby Laboratories Licensing Corporation	Low latency data encoder
US6809195B1 (en)	2000-08-16	2004-10-26	Isis Pharmaceuticals, Inc.	Process for the preparation of oligonucleotides
US6559279B1 (en)	2000-09-08	2003-05-06	Isis Pharmaceuticals, Inc.	Process for preparing peptide derivatized oligomeric compounds
EP1191097A1 (en)	2000-09-21	2002-03-27	Leids Universitair Medisch Centrum	Induction of exon skipping in eukaryotic cells
US6376190B1 (en)	2000-09-22	2002-04-23	Somalogic, Inc.	Modified SELEX processes without purified protein
US7312325B2 (en)	2000-09-26	2007-12-25	Duke University	RNA aptamers and methods for identifying the same
GB0024752D0 (en)	2000-10-10	2000-11-22	Univ Belfast	Oxidative halogenation of aromatic compounds
EP1332227A4 (en)	2000-10-16	2005-08-24	Gilead Sciences Inc	NUCLEAR ACID LIGHTS ON THE PROSTATE-SPECIFIC MEMBRANEANT
AU2002244337B2 (en)	2000-10-18	2005-08-11	Glaxosmithkline Biologicals S.A.	Vaccines
US6682889B1 (en)	2000-11-08	2004-01-27	Becton, Dickinson And Company	Amplification and detection of organisms of the Chlamydiaceae family
JP2002165594A (ja)	2000-11-29	2002-06-11	National Institute Of Advanced Industrial & Technology	Ｃ型肝炎ウイルスのｉｒｅｓ及びｎｓ３プロテアーゼを標的とするｒｎａ分子
NL1016978C2 (nl)	2000-12-22	2002-06-25	Robert Jan Colenbrander	Inrichting en werkwijze voor het verpakken en bereiden van voedsel en werkwijze voor het vervaardigen van een dergelijke inrichting.
SK286630B6 (sk)	2001-01-22	2009-02-05	Merck & Co., Inc.	Nukleozidové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie
US8008459B2 (en)	2001-01-25	2011-08-30	Evolva Sa	Concatemers of differentially expressed multiple genes
WO2002059297A2 (en)	2001-01-25	2002-08-01	Evolva Biotech A/S	A library of a collection of cells
EP1354035B1 (en)	2001-01-26	2016-08-24	Commonwealth Scientific and Industrial Research Organisation	Methods and means for producing efficient silencing construct using recombinational cloning
EP1383782A1 (en)	2001-03-26	2004-01-28	Sirna Therpeutics, Inc.	Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication
US20050277133A1 (en)	2001-05-18	2005-12-15	Sirna Therapeutics, Inc.	RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
US20030207804A1 (en)	2001-05-25	2003-11-06	Muthiah Manoharan	Modified peptide nucleic acids
GB0113523D0 (en)	2001-06-04	2001-07-25	Torotrak Dev Ltd	An Hydraulic control circuit for a continuosly variable transmission
US20030069410A1 (en)	2001-06-14	2003-04-10	Isis Pharmaceuticals, Inc.	Methods for preparing oligonucleotides having chiral phosphorothioate linkages
SK15762003A3 (sk)	2001-06-29	2005-01-03	Chiron Corporation	Kompozícia vakcíny HCV E1E2
CA2452458A1 (en)	2001-07-03	2003-01-16	Isis Pharmaceuticals, Inc.	Nuclease resistant chimeric oligonucleotides
US7205399B1 (en)	2001-07-06	2007-04-17	Sirna Therapeutics, Inc.	Methods and reagents for oligonucleotide synthesis
US6440739B1 (en)	2001-07-17	2002-08-27	Isis Pharmaceuticals, Inc.	Antisense modulation of glioma-associated oncogene-2 expression
US7425545B2 (en)	2001-07-25	2008-09-16	Isis Pharmaceuticals, Inc.	Modulation of C-reactive protein expression
US7888324B2 (en)	2001-08-01	2011-02-15	Genzyme Corporation	Antisense modulation of apolipoprotein B expression
US7407943B2 (en)	2001-08-01	2008-08-05	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein B expression
US6455308B1 (en)	2001-08-01	2002-09-24	Isis Pharmaceuticals, Inc.	Antisense modulation of serum amyloid A4 expression
US7227014B2 (en)	2001-08-07	2007-06-05	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein (a) expression
US7259150B2 (en)	2001-08-07	2007-08-21	Isis Pharmaceuticals, Inc.	Modulation of apolipoprotein (a) expression
WO2003020884A2 (en)	2001-08-14	2003-03-13	The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services	Method for rapid generation of mature dendritic cells
CA2458393A1 (en)	2001-08-24	2003-03-06	Massachusetts Institute Of Technology	Reagents that facilitate the purification of compounds synthesized on a solid support
US7049122B2 (en)	2001-09-21	2006-05-23	Academia Sinica	Mutant-type lipases and applications thereof
US6933288B2 (en)	2002-02-04	2005-08-23	Isis Pharmaceuticals, Inc.	Pyranosyl cytosines: pharmaceutical formulations and methods
JP4348044B2 (ja)	2002-02-12	2009-10-21	株式会社キラルジェン	立体規則性の高いジヌクレオシドホスホロチオエートの製造法
US8232383B2 (en)	2002-02-20	2012-07-31	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20050096284A1 (en)	2002-02-20	2005-05-05	Sirna Therapeutics, Inc.	RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
WO2003106476A1 (en)	2002-02-20	2003-12-24	Sirna Therapeutics, Inc	Nucleic acid mediated inhibition of enterococcus infection and cytolysin toxin activity
US7288376B2 (en)	2002-03-22	2007-10-30	Council Of Scientific And Industrial Research	Method of detection of SP-A2 gene variants useful for prediction of predisposition to aspergillosis
US20040102394A1 (en)	2002-11-23	2004-05-27	Isis Pharmaceuticals Inc.	Modulation of huntingtin interacting protein 2 expression
WO2003097662A1 (en)	2002-05-15	2003-11-27	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein b expression
WO2003099840A1 (en)	2002-05-24	2003-12-04	Isis Pharmaceuticals, Inc.	Oligonucleotides having modified nucleoside units
AU2003241621A1 (en)	2002-05-24	2003-12-12	Isis Pharmaceuticals, Inc.	Oligonucleotides having modified nucleoside units
WO2003102212A2 (en)	2002-05-31	2003-12-11	Regents Of The University Of Minnesota	In vitro evaluation of nucleic acid ligands
US7507808B2 (en)	2002-12-12	2009-03-24	Isis Pharmaceuticals, Inc.	Modulation of endothelial lipase expression
AU2003248708A1 (en)	2002-06-17	2003-12-31	Isis Pharmaceuticals, Inc.	Oligomeric compounds that include carbocyclic nucleosides and their use in gene modulation
BR0311995A (pt)	2002-06-20	2005-04-05	Cytos Biotechnology Ag	Partìculas semelhantes a vìrus empacotadas para o uso como adjuvantes: método de preparação e uso
WO2004003228A1 (en)	2002-07-01	2004-01-08	Unisearch Limited	Genotyping method
US8101348B2 (en)	2002-07-10	2012-01-24	Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V.	RNA-interference by single-stranded RNA molecules
US20040023905A1 (en)	2002-07-31	2004-02-05	Isis Pharmaceuticals Inc.	Antisense modulation of LAR expression
EP1386972A1 (en)	2002-08-01	2004-02-04	Noxxon Pharma AG	Method and apparatus for designing a nucleic acid having a desired property
US20050255086A1 (en)	2002-08-05	2005-11-17	Davidson Beverly L	Nucleic acid silencing of Huntington's Disease gene
US20050042646A1 (en)	2002-08-05	2005-02-24	Davidson Beverly L.	RNA interference suppresion of neurodegenerative diseases and methods of use thereof
US20080274989A1 (en)	2002-08-05	2008-11-06	University Of Iowa Research Foundation	Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof
AU2003261449A1 (en)	2002-08-07	2004-02-25		Compositions for rna interference and methods of use thereof
AR040996A1 (es)	2002-08-19	2005-04-27	Coley Pharm Group Inc	Acidos nucleicos inmunoestimuladores
US7414116B2 (en)	2002-08-23	2008-08-19	Illumina Cambridge Limited	Labelled nucleotides
BR0314236A (pt)	2002-09-13	2005-08-09	Replicor Inc	Formulação de oligonucleotìdeo, composição farmacêutica, kit, composto antiviral, preparação de oligonucleotìdeo e métodos para seleção de um oligonucleotìdeo antiviral para uso como um agente antiviral, para profilaxia ou tratamento de uma infecção viral em um paciente, para tratamento profilático de câncer causado por oncovìrus, para identificação de um composto que altera a ligação de um oligonucleotìdeo a pelo menos um componente viral, para purificação da ligação de oligonucleotìdeos a pelo menos um componente viral e para enriquecimento de oligonucleotìdeos a partir de um agrupamento de oligonucleotìdeos
US7030230B2 (en)	2002-10-25	2006-04-18	Isis Pharmaceuticals, Inc.	Process of purifying phosphoramidites
CN1753687A (zh)	2002-10-29	2006-03-29	科勒制药集团股份有限公司	Cpg寡核苷酸在治疗丙型肝炎病毒感染中的应用
WO2004041889A2 (en)	2002-11-05	2004-05-21	Isis Pharmaceuticals, Inc.	Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
AU2003295389A1 (en)	2002-11-05	2004-06-03	Isis Pharmaceuticals, Inc.	Conjugated oligomeric compounds and their use in gene modulation
AU2003291755A1 (en)	2002-11-05	2004-06-07	Isis Pharmaceuticals, Inc.	Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use
AU2003291721A1 (en)	2002-11-05	2004-06-03	Isis Pharmaceuticals, Inc.	Phosphorous-linked oligomeric compounds and their use in gene modulation
US7381527B2 (en)	2002-11-06	2008-06-03	Council Of Scientific And Industrial Research	Method of detection of SP-A2 gene variants
US7511131B2 (en)	2002-11-13	2009-03-31	Genzyme Corporation	Antisense modulation of apolipoprotein B expression
EP2336318B1 (en)	2002-11-13	2013-04-24	Genzyme Corporation	Antisense modulation of apolipoprotein b expression
AU2003295600A1 (en)	2002-11-14	2004-06-15	Dharmacon, Inc.	Functional and hyperfunctional sirna
CA2518475C (en)	2003-03-07	2014-12-23	Alnylam Pharmaceuticals, Inc.	Irna agents comprising asymmetrical modifications
GB0305422D0 (en)	2003-03-10	2003-04-16	Univ Open	Detection, monitoring and treatment of cancer
AU2003225410A1 (en)	2003-03-21	2004-10-11	Academisch Ziekenhuis Leiden	Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
GB0306657D0 (en)	2003-03-24	2003-04-30	Avecia Ltd	Process and compounds
US7537767B2 (en)	2003-03-26	2009-05-26	Cytis Biotechnology Ag	Melan-A- carrier conjugates
AU2004224761A1 (en)	2003-03-26	2004-10-07	Cytos Biotechnology Ag	HIV-peptide-carrier-conjugates
ITRM20030149A1 (it)	2003-04-02	2004-10-03	Giuliani Spa	Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
US7598227B2 (en)	2003-04-16	2009-10-06	Isis Pharmaceuticals Inc.	Modulation of apolipoprotein C-III expression
JP2007525177A (ja)	2003-04-21	2007-09-06	アーケミックスコーポレイション	血小板由来増殖因子に対する安定化アプタマーおよび腫瘍治療剤としてのそれらの使用
US7045306B2 (en)	2003-04-28	2006-05-16	The General Hospital Corporation	Method for identifying compounds in vitro that modulate the dysregulation of transcription of transcription mediated by mutant huntingtin protein
US7214491B2 (en)	2003-05-07	2007-05-08	E. I. Du Pont De Nemours And Company	Δ-12 desaturase gene suitable for altering levels of polyunsaturated fatty acids in oleaginous yeasts
US7589189B2 (en)	2003-05-14	2009-09-15	Japan Science And Technology Agency	Inhibition of the expression of huntingtin gene
JP4579911B2 (ja)	2003-06-03	2010-11-10	アイシス・ファーマシューティカルズ・インコーポレイテッド	スルビビン発現の調節
MXPA05013922A (es)	2003-06-20	2006-02-24	Coley Pharm Group Inc	Antagonistas de receptor tipo toll de molecula pequena.
US8969314B2 (en)	2003-07-31	2015-03-03	Regulus Therapeutics, Inc.	Methods for use in modulating miR-122a
US7683036B2 (en)	2003-07-31	2010-03-23	Regulus Therapeutics Inc.	Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
JP2005089441A (ja)	2003-08-08	2005-04-07	Toudai Tlo Ltd	立体規則性の高いリン原子修飾ヌクレオチド類縁体の製造法
JP2011088935A (ja)	2003-08-08	2011-05-06	Chiralgen Ltd	リン原子修飾ヌクレオチド類縁体の製造のための光学活性ヌクレオシド３’−ホスホロアミダイト
US7825235B2 (en)	2003-08-18	2010-11-02	Isis Pharmaceuticals, Inc.	Modulation of diacylglycerol acyltransferase 2 expression
EP1661905B9 (en)	2003-08-28	2012-12-19	IMANISHI, Takeshi	Novel artificial nucleic acids of n-o bond crosslinkage type
JP4616175B2 (ja)	2003-09-02	2011-01-19	株式会社キラルジェン	５’−ホスフィチル化モノマーおよびｈ−ホスホネートオリゴヌクレオチド誘導体の製造方法
JP4580870B2 (ja)	2003-09-02	2010-11-17	株式会社キラルジェン	リボヌクレオチド又はリボヌクレオチド誘導体の製造方法
US20050053981A1 (en)	2003-09-09	2005-03-10	Swayze Eric E.	Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
US20050074801A1 (en)	2003-09-09	2005-04-07	Monia Brett P.	Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometry
PL1667522T3 (pl)	2003-09-09	2018-06-29	Geron Corporation	Zmodyfikowane oligonukleotydy do hamowania telomerazy
US8680063B2 (en)	2003-09-12	2014-03-25	University Of Massachusetts	RNA interference for the treatment of gain-of-function disorders
DK2821085T3 (da)	2003-09-12	2020-08-03	Univ Massachusetts	Rna-interferens til behandling af "gain-of-function"-forstyrrelser
WO2008005562A2 (en)	2006-07-07	2008-01-10	University Of Massachusetts	Rna silencing compositions and methods for the treatment of huntington's disease
GB0323968D0 (en)	2003-10-13	2003-11-19	Glaxosmithkline Biolog Sa	Immunogenic compositions
EP1678303A2 (en)	2003-10-30	2006-07-12	Coley Pharmaceutical GmbH	C-class oligonucleotide analogs with enhanced immunostimulatory potency
US20050239102A1 (en)	2003-10-31	2005-10-27	Verdine Gregory L	Nucleic acid binding oligonucleotides
US7846436B2 (en)	2003-11-28	2010-12-07	Chemgenes Corporation	Oligonucleotides and related compounds
WO2005070859A1 (ja)	2004-01-27	2005-08-04	Takeshi Wada	フルオラス担体およびそれを用いたオリゴヌクレオチド誘導体の製造方法
US20050176045A1 (en)	2004-02-06	2005-08-11	Dharmacon, Inc.	SNP discriminatory siRNA
WO2005076744A2 (en)	2004-02-18	2005-08-25	Frutarom Ltd.	Method for the preparation of peptide-oligonucleotide conjugates
JP3976742B2 (ja)	2004-02-27	2007-09-19	江守商事株式会社	インターフェロンアルファを誘導する免疫刺激オリゴヌクレオチド
US20060193821A1 (en)	2004-03-05	2006-08-31	Diener John L	Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
WO2005085272A1 (ja)	2004-03-05	2005-09-15	Takeshi Wada	ボラノホスフェートモノマーおよびそれを用いたオリゴヌクレオチド誘導体の製造方法
WO2005092909A1 (ja)	2004-03-25	2005-10-06	Toudai Tlo, Ltd.	立体規則性の高いリボヌクレオチド類縁体及びデオキシリボヌクレオチド類縁体の製造法
US20050244869A1 (en)	2004-04-05	2005-11-03	Brown-Driver Vickie L	Modulation of transthyretin expression
JP2007531794A (ja)	2004-04-05	2007-11-08	アルニラムファーマスーティカルズインコーポレイテッド	オリゴヌクレオチドの合成および精製に使用する方法および反応試薬
CA2564311A1 (en)	2004-04-26	2005-12-01	Sharon Cload	Nucleic acid ligands specific to immunoglobulin e and their use as atopic disease therapeutics
TWI350168B (en)	2004-05-07	2011-10-11	Incyte Corp	Amido compounds and their use as pharmaceuticals
AU2005248410B2 (en)	2004-05-27	2010-04-22	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Differential expression of molecules associated with acute stroke
US7759318B1 (en)	2004-05-28	2010-07-20	Isis Pharmaceuticals, Inc.	Identification of novel pathways, genes and promoter motifs regulating adipogenesis
EP2933332A1 (en)	2004-06-28	2015-10-21	The University Of Western Australia	Antisense oligonucleotides for inducing exon skipping and methods of use thereof
ES2401114T3 (es)	2004-08-10	2013-04-17	Genzyme Corporation	Modulación antisentido de la expresión de apolipoproteína B
AU2005275801B2 (en)	2004-08-26	2012-05-10	Nippon Shinyaku Co., Ltd.	Phosphoramidite compound and method for producing oligo-RNA
KR20070101226A (ko)	2004-09-07	2007-10-16	아케믹스 코포레이션	앱타머의 약화학
EP1789096A4 (en)	2004-09-07	2009-07-08	Archemix Corp	APTAMERS FOR THE VON WILLEBRAND FACTOR AND ITS USE AS THERAPEUTICS FOR THROMBOTIC DISEASES
US7884086B2 (en)	2004-09-08	2011-02-08	Isis Pharmaceuticals, Inc.	Conjugates for use in hepatocyte free uptake assays
US20090203132A1 (en)	2004-09-09	2009-08-13	Swayze Eric E	Pyrrolidinyl groups for attaching conjugates to oligomeric compounds
US7919472B2 (en)	2004-09-17	2011-04-05	Isis Pharmaceuticals, Inc.	Enhanced antisense oligonucleotides
CA2582464A1 (en)	2004-10-13	2006-04-27	Sanjay Bhanot	Antisense modulation of ptp1b expression
KR100721928B1 (ko)	2004-11-05	2007-05-28	주식회사 바이오씨에스	ＣｐＧ 올리고데옥시뉴클레오티드를 함유하는 피부질환의치료 또는 예방용 약학적 조성물
EP1657307A1 (en)	2004-11-16	2006-05-17	Immunotech S.A.	Oligonucleotides that induce the secretion of GM-CSF
US8003619B2 (en)	2004-12-09	2011-08-23	Alnylam Pharmaceuticals, Inc.	Method of stimulating an immune response and inhibiting expression of a gene using an oligonucleotide
WO2006065751A2 (en)	2004-12-13	2006-06-22	Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services	Cpg oligonucleotide prodrugs, compositions thereof and associated therapeutic methods
WO2006066260A2 (en)	2004-12-17	2006-06-22	Thiosense, Inc.	Compositions of and methods for producing phosphorus-chiral monomers and oligomers
US20060183763A1 (en)	2004-12-31	2006-08-17	Pfizer Inc	Novel pyrrolidyl derivatives of heteroaromatic compounds
US20060166901A1 (en)	2005-01-03	2006-07-27	Yu Ruey J	Compositions comprising O-acetylsalicyl derivatives of aminocarbohydrates and amino acids
JP4836145B2 (ja)	2005-01-28	2011-12-14	クウォン，ヒュン−ジョ	マイコバクテリアに由来する、免疫機能刺激用、免疫疾患治療用、アトピー性皮膚炎治療用および／または正常免疫細胞保護用オリゴヌクレオチド
US20080009455A9 (en)	2005-02-24	2008-01-10	Coley Pharmaceutical Group, Inc.	Immunostimulatory oligonucleotides
JP2006248949A (ja)	2005-03-09	2006-09-21	Univ Nagoya	ヌクレオシド誘導体、ヌクレオチド誘導体及びそれらの製造方法
ATE534652T1 (de)	2005-04-01	2011-12-15	Univ California	Phosphono-pent-2-en-1-yl-nukleoside und analoga
NZ562954A (en)	2005-05-05	2009-10-30	Antisense Pharma Gmbh	Use of low doses of oligonucleotides antisense to TGF-beta, VEGF, interleukin-10, C-JUN, C-FOS or prostaglandin E2 genes in the treatment of tumors
US7902352B2 (en)	2005-05-06	2011-03-08	Medtronic, Inc.	Isolated nucleic acid duplex for reducing huntington gene expression
WO2006121960A2 (en)	2005-05-06	2006-11-16	Medtronic, Inc.	Methods and sequences to suppress primate huntington gene expression
EP1896850A2 (en)	2005-06-15	2008-03-12	The Ohio State University Research Foundation	Aptamers that bind to prion protein
US10242753B2 (en)	2005-06-17	2019-03-26	University Of Washington	Method for measuring strength of associations of multidimensional traits
EP3470072A1 (en)	2005-06-23	2019-04-17	Biogen MA Inc.	Compositions and methods for modulation of smn2 splicing
US9133517B2 (en)	2005-06-28	2015-09-15	Medtronics, Inc.	Methods and sequences to preferentially suppress expression of mutated huntingtin
WO2007002904A2 (en)	2005-06-28	2007-01-04	Medtronic, Inc.	Methods and sequences to preferentially suppress expression of mutated huntingtin
WO2007005941A2 (en)	2005-07-05	2007-01-11	President And Fellows Of Harvard College	Liver targeted conjugates
JP4984634B2 (ja)	2005-07-21	2012-07-25	ソニー株式会社	物理情報取得方法および物理情報取得装置
CA2641599C (en)	2005-07-28	2012-07-10	Id-Fish Technology, Inc.	Method for improving cell permeability to foreign particles
MEP0208A (xx)	2005-08-26	2010-02-10	Archemix Corp	Aptameri koji vezuje trombin sa visokim afininitetom
US8501703B2 (en) *	2005-08-30	2013-08-06	Isis Pharmaceuticals, Inc.	Chimeric oligomeric compounds for modulation of splicing
CA2622765A1 (en)	2005-09-15	2007-03-29	Duke University	Focused libraries, functional profiling, laser selex and deselex
US7700567B2 (en)	2005-09-29	2010-04-20	Supergen, Inc.	Oligonucleotide analogues incorporating 5-aza-cytosine therein
US20070077993A1 (en)	2005-09-30	2007-04-05	Midgley Timothy M	Method and apparatus for collecting user game play data and crediting users in a gaming environment
EP2982679A1 (en)	2005-10-12	2016-02-10	Idera Pharmaceuticals, Inc.	Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
US9308252B2 (en)	2005-10-27	2016-04-12	Cook Biotech, Inc.	Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins
WO2007049416A1 (ja)	2005-10-28	2007-05-03	Tosoh Corporation	カロテノイド合成微生物の作製方法およびカロテノイドの製造方法
JP5111385B2 (ja)	2005-10-28	2013-01-09	アルナイラムファーマシューティカルズ，インコーポレイテッド	ハンチンチン遺伝子の発現を抑制するための組成物および方法
AU2006315632A1 (en)	2005-11-11	2007-05-24	Pfizer, Inc.	Combinations and methods of using an immunomodulatory oligodeoxynucleotide
WO2007064291A1 (en)	2005-11-30	2007-06-07	Jyoti Chattopadhyaya	Method and compounds for rna synthesis
CA2632968A1 (en)	2005-12-02	2007-06-07	Isis Pharmaceuticals, Inc.	Antibacterial 4,5-substituted aminoglycoside analogs having multiple substituents
US8076303B2 (en) *	2005-12-13	2011-12-13	Spring Bank Pharmaceuticals, Inc.	Nucleotide and oligonucleotide prodrugs
NZ568692A (en)	2005-12-21	2011-07-29	Pfizer Prod Inc	Carbonylamino pyrrolopyrazoles, potent kinase inhibitors
EP1991677A2 (en)	2006-01-26	2008-11-19	Isis Pharmaceuticals, Inc.	Compositions and their uses directed to huntingtin
WO2007090071A2 (en)	2006-01-27	2007-08-09	Isis Pharmaceuticals, Inc.	6-modified bicyclic nucleic acid analogs
DK2135949T3 (da)	2006-02-14	2013-02-04	Noxxon Pharma Ag	MCP-1-bindende nukleinsyrer
DK2405002T3 (da)	2006-02-15	2015-01-05	Adiutide Pharmaceuticals Gmbh	Sammensætninger og fremgangsmåder til oligonukleotidformuleringer
NZ571791A (en)	2006-03-08	2012-03-30	Archemix Llc	Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders
US8383660B2 (en)	2006-03-10	2013-02-26	Pfizer Inc.	Dibenzyl amine compounds and derivatives
CN101454315B (zh)	2006-03-31	2016-08-17	应用生物系统有限责任公司	用于合成罗丹明-标记的寡核苷酸的试剂
EP2010679A2 (en)	2006-04-06	2009-01-07	Ibis Biosciences, Inc.	Compositions for the use in identification of fungi
ATE476424T1 (de)	2006-04-20	2010-08-15	Hoffmann La Roche	Diazepanderivate als modulatoren von chemokinrezeptoren
WO2007123386A1 (es)	2006-04-24	2007-11-01	Sigma Alimentos, S.A. De C.V.	Método para la detección y cuantificación múltiple y simultánea de patógenos mediante la reacción en cadena de la polimerasa en tiempo real
EP2018436A2 (en)	2006-04-25	2009-01-28	Immune Disease Institute Inc.	Targeted delivery to leukocytes using non-protein carriers
GB0608838D0 (en)	2006-05-04	2006-06-14	Novartis Ag	Organic compounds
WO2007131232A2 (en)	2006-05-05	2007-11-15	Isis Pharmaceuticals, Inc.	Compositions and their uses directed to ptpr alpha
JP2009536222A (ja)	2006-05-05	2009-10-08	アイシスファーマシューティカルズ，インコーポレーテッド	Ｐｃｓｋ９の発現を調節するための化合物および方法
US20090012120A1 (en)	2006-05-10	2009-01-08	Board Of Trustees Of Michigan State University	Synthesis of N-heterocycles, beta-amino acids, and allyl amines via aza-payne mediated reaction of ylides and hydroxy aziridines
AU2007249349B2 (en)	2006-05-11	2012-03-08	Isis Pharmaceuticals, Inc.	5'-Modified bicyclic nucleic acid analogs
US7666854B2 (en)	2006-05-11	2010-02-23	Isis Pharmaceuticals, Inc.	Bis-modified bicyclic nucleic acid analogs
RU2568579C2 (ru)	2006-05-26	2015-11-20	ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика"	Введение противосвертывающей системы reg1
CN101460620B (zh)	2006-05-31	2012-02-15	东丽株式会社	免疫刺激寡核苷酸及其药物用途
US8097596B2 (en)	2006-06-30	2012-01-17	Lakewood-Amedex, Inc.	Compositions and methods for the treatment of muscle wasting
AU2007272906B2 (en)	2006-07-12	2013-01-31	The Regents Of The University Of California	Transducible delivery of nucleic acids by reversible phosphotriester charge neutralization protecting groups
US9233106B2 (en)	2006-07-12	2016-01-12	Cornell Research Foundation, Inc.	Inhibition of beta-amyloid peptide aggregation
KR101466931B1 (ko)	2006-07-18	2014-12-02	녹손 파르마 아게	Sdf-1 결합형 b형 핵산분자
CN100503824C (zh)	2006-07-20	2009-06-24	武汉大学	抗结核杆菌感染的小分子核苷酸dna适配子及其制备方法
AU2007275301A1 (en)	2006-07-20	2008-01-24	Amgen Inc.	Substituted azole aromatic heterocycles as inhibitors of 11-beta-HSD-1
US8101585B2 (en)	2006-08-04	2012-01-24	Isis Pharmaceuticals, Inc.	Compositions and methods for the modulation of JNK proteins
AT504194B1 (de)	2006-09-07	2008-07-15	Oesterr Rotes Kreuz	Bakteriennachweis
EP1897562A1 (en)	2006-09-08	2008-03-12	Bayer Schering Pharma Aktiengesellschaft	Aptamers labelled with Gallium-68
US8138330B2 (en)	2006-09-11	2012-03-20	Sigma-Aldrich Co. Llc	Process for the synthesis of oligonucleotides
PT2078080E (pt)	2006-09-27	2015-09-18	Coley Pharm Gmbh	Análogos dos oligonucleotídeos cpg que contêm análogos t hidrofóbicos com atividade imunoestimulante potenciada
ES2526295T5 (es)	2006-10-18	2021-05-04	Ionis Pharmaceuticals Inc	Compuestos antisentido
WO2008051763A1 (en)	2006-10-23	2008-05-02	Irm Llc	Cathepsin proteases inhibitors
AU2007353120A1 (en)	2006-10-26	2008-11-20	Coley Pharmaceutical Gmbh	Oligoribonucleotides and uses thereof
FR2908414B1 (fr)	2006-11-13	2012-01-20	Centre Nat Rech Scient	Immobilisation de proteines membranaires sur un support par l'intermediaire d'une molecule amphiphile
CN101534824A (zh)	2006-11-17	2009-09-16	艾博特公司	作为化学活素受体拮抗剂的氨基吡咯烷
US8093222B2 (en)	2006-11-27	2012-01-10	Isis Pharmaceuticals, Inc.	Methods for treating hypercholesterolemia
CA2670563A1 (en)	2006-11-27	2008-06-05	Isis Pharmaceuticals, Inc.	Methods for treating hypercholesterolemia
KR100861108B1 (ko)	2006-11-28	2008-09-30	(주) 벡스코아	씨형 간염 바이러스 레플리콘 증식을 억제하는 알엔에이분해효소 저항성 알엔에이 압타머
CN101610671A (zh)	2006-12-12	2009-12-23	艾德拉药物股份有限公司	合成的tlr9激动剂
UY30892A1 (es)	2007-02-07	2008-09-02	Smithkline Beckman Corp	Inhibidores de la actividad akt
WO2008101157A1 (en)	2007-02-15	2008-08-21	Isis Pharmaceuticals, Inc.	5'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom
CA2682082A1 (en)	2007-03-24	2008-10-02	Genzyme Corporation	Administering antisense oligonucleotides complementary to human apolipoprotein b
JP2010525826A (ja)	2007-05-03	2010-07-29	ロゼッタインファーマティックスエルエルシー	癌を治療するためのｍｉｒ３４治療剤を含む組成物
US7943591B2 (en)	2007-05-11	2011-05-17	Adynxx, Inc.	Gene expression and pain
CA2687441A1 (en) *	2007-05-17	2008-11-27	Coley Pharmaceutical Group, Inc.	Class a oligonucleotides with immunostimulatory potency
JP5322927B2 (ja)	2007-05-24	2013-10-23	杏林製薬株式会社	１４位置換基に複素芳香環カルボン酸構造を有するムチリン誘導体
GB0710186D0 (en)	2007-05-29	2007-07-04	Texas Instr Denmark	PWM loop with minimum allasing error property
CA2688321A1 (en)	2007-05-30	2008-12-11	Isis Pharmaceuticals, Inc.	N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
AU2008258599B2 (en)	2007-06-05	2013-06-13	Nsab, Filial Af Neurosearch Sweden Ab, Sverige	Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission
DK2173760T4 (da)	2007-06-08	2016-02-08	Isis Pharmaceuticals Inc	Carbocycliske bicycliske nukleinsyreanaloge
EP2164865A2 (en)	2007-06-13	2010-03-24	Hochschule Mannheim	Compounds for the modulation of huntingtin aggregation, methods and means for identifying such compounds
EP2014769B1 (en)	2007-06-18	2010-03-31	Commissariat à l'Energie Atomique	Reversible siRNAa-based silencing of mutated and endogenous wild-type huntingtin gene and its application for the treatment of Huntington's disease
AU2008272918B2 (en)	2007-07-05	2012-09-13	Isis Pharmaceuticals, Inc.	6-disubstituted bicyclic nucleic acid analogs
EP2357231A2 (en)	2007-07-09	2011-08-17	Idera Pharmaceuticals, Inc.	Stabilized immune modulatory RNA (SIMRA) compounds
EP2185723A4 (en)	2007-07-31	2011-01-12	Univ Saskatchewan	EFFECT OF A GENETIC VARIATION IN THE GENESIS OF PROMELANIN CONCENTRATING HORMONE ON THE MEAT PROPERTIES IN BOVINE ANIMALS
US7812003B2 (en)	2007-08-02	2010-10-12	Safe Stephen H	Antisense microRNA and uses therefor
JP2010536787A (ja)	2007-08-15	2010-12-02	イデラファーマシューティカルズインコーポレイテッド	Ｔｏｌｌ様受容体モジュレータ
WO2009046141A2 (en)	2007-10-01	2009-04-09	Isis Pharmaceuticals, Inc.	Antisense modulation of fibroblast growth factor receptor 4 expression
KR100886139B1 (ko)	2007-11-13	2009-02-27	주식회사 삼천리제약	올리고뉴클레오타이드의 제조방법
AR069869A1 (es)	2007-12-21	2010-02-24	Exelixis Inc	Derivados de benzofuro[3,2-d]pirimidinas inhibidores de proteinquinasas,composiciones farmaceuticas que los comprenden y usos de los mismos en el tratamiento del cancer.
TWI340765B (en)	2007-12-26	2011-04-21	Ind Tech Res Inst	Oligonucleotide sequences and dna chip for identifying filamentous microorganisms and the identification method thereof
US20100309376A1 (en)	2008-01-15	2010-12-09	Yungchun Lei	Multimedia Presenting System, Multimedia Processing Apparatus Thereof, and Method for Presenting Video and Audio Signals
WO2009089659A1 (en)	2008-01-18	2009-07-23	Shanghai Targetdrug Co., Ltd.	Pyrollidine-based compounds
EP2240768A1 (en)	2008-02-04	2010-10-20	Galapagos N.V.	Target sequences and methods to identify the same, useful in treatment of neurodegenerative diseases
JP2009190983A (ja)	2008-02-12	2009-08-27	Tokyo Institute Of Technology	オリゴヌクレオチド誘導体
WO2009117589A1 (en)	2008-03-21	2009-09-24	Isis Pharmaceuticals, Inc.	Oligomeric compounds comprising tricyclic nucleosides and methods for their use
US20110130440A1 (en)	2008-03-26	2011-06-02	Alnylam Pharmaceuticals, Inc.	Non-natural ribonucleotides, and methods of use thereof
GB2471806B (en)	2008-04-03	2012-12-19	Spring Bank Pharmaceuticals Inc	Compositions and methods for treating viral infections
US9290534B2 (en)	2008-04-04	2016-03-22	Ionis Pharmaceuticals, Inc.	Oligomeric compounds having at least one neutrally linked terminal bicyclic nucleoside
US8679750B2 (en)	2008-05-09	2014-03-25	The University Of British Columbia	Methods and compositions for the treatment of Huntington'S disease
CA2726866A1 (en)	2008-05-09	2009-11-12	The University Of British Columbia	Methods and compositions for the treatment of huntington's disease
US8541387B2 (en)	2008-05-22	2013-09-24	Isis Pharmaceuticals, Inc.	Modulation of SMRT expression
WO2009143391A2 (en)	2008-05-22	2009-11-26	Isis Pharmaceuticals, Inc	Methods for modulation expression of creb
WO2009143390A2 (en)	2008-05-22	2009-11-26	Isis Pharmaceuticals, Inc.	Methods for modulating expression of rbp4
WO2009148605A2 (en)	2008-06-04	2009-12-10	Isis Pharmaceuticals, Inc.	Methods for treating hypercholesterolemia
US20110201599A1 (en)	2008-07-03	2011-08-18	Exelixis, Inc.	CDK Modulators
US8691971B2 (en)	2008-09-23	2014-04-08	Scott G. Petersen	Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating RNA interference
DK2361256T3 (da)	2008-09-24	2013-07-01	Isis Pharmaceuticals Inc	Cyclohexenyl-nukleinsyreanaloger
DK2356129T3 (da)	2008-09-24	2013-05-13	Isis Pharmaceuticals Inc	Substituerede alpha-L-bicykliske nukleosider
CA2739788A1 (en)	2008-10-07	2010-04-15	President And Fellows Of Harvard College	Telomerase inhibitors that bind to the cr4-cr5 domain of the rna component of human telomerase and methods of use thereof
CA2962219C (en)	2008-10-22	2020-08-25	Quark Pharmaceuticals, Inc.	Methods for treating eye disorders
US20120059045A1 (en)	2008-10-24	2012-03-08	Isis Pharmaceuticals, Inc.	Methods of using oligomeric compounds comprising 2'-substituted nucleosides
CN102282155B (zh) *	2008-12-02	2017-06-09	日本波涛生命科学公司	磷原子修饰的核酸的合成方法
EP2382227A1 (en)	2008-12-23	2011-11-02	Girindus America, Inc.	Sulfurizing reagents and their use for oligonucleotides synthesis
WO2010080953A1 (en)	2009-01-08	2010-07-15	Isis Pharmaceuticals, Inc.	Transgenic murine model of human lipoprotein metabolism, hypercholesterolemia and cardiovascular disease
WO2010091301A1 (en)	2009-02-06	2010-08-12	Isis Pharmaceuticals, Inc.	Oligomeric compounds and excipients
CN102361981A (zh)	2009-02-10	2012-02-22	艾德拉药物股份有限公司	Tlr7的合成rna基激动剂
AU2010221419B2 (en)	2009-03-02	2015-10-01	Alnylam Pharmaceuticals, Inc.	Nucleic acid chemical modifications
EP2408796B1 (en) *	2009-03-16	2020-04-22	Ionis Pharmaceuticals, Inc.	Targeting Apolipoprotein B for the reduction of Apolipoprotein C-III
WO2010118263A1 (en)	2009-04-08	2010-10-14	University Of Massachusetts	Single-nucleotide polymorphism (snp) targeting therapies for the treatment of huntington's disease
US20120156138A1 (en)	2009-04-14	2012-06-21	Smith Larry J	Methods and Compositions for the Treatment of Medical Conditions Involving Cellular Reprogramming
US9260493B2 (en)	2009-05-07	2016-02-16	The Regents Of The University Of California	Transducible delivery of nucleic acids using modified dsRNA binding domains
US20120142763A1 (en)	2009-06-01	2012-06-07	The Regents Of The University Of California	Nucleic acid delivery compositions and methods of use thereof
CA2764374C (en)	2009-06-05	2019-11-19	Infectious Disease Research Institute	Synthetic glucopyranosyl lipid adjuvants
ES2699827T3 (es)	2009-06-17	2019-02-13	Biogen Ma Inc	Composiciones y métodos para la modulación de corte y empalme de SMN2 en un sujeto
RU2612521C2 (ru) *	2009-07-06	2017-03-09	Онтории, Инк.	Новые пролекарства нуклеиновых кислот и способы их применения
WO2011005764A1 (en)	2009-07-06	2011-01-13	Ada Technologies, Inc.	Electrochemical device and method for long-term measurement of hypohalites
WO2011005860A2 (en)	2009-07-07	2011-01-13	Alnylam Pharmaceuticals, Inc.	5' phosphate mimics
EP2451974A2 (en)	2009-07-08	2012-05-16	Idera Pharmaceuticals, Inc.	Oligonucleotide-based compounds as inhibitors of toll-like receptors
WO2011015572A1 (en)	2009-08-03	2011-02-10	Galapagos Nv	Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
WO2011015573A1 (en)	2009-08-03	2011-02-10	Galapagos Nv	Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
US9012421B2 (en)	2009-08-06	2015-04-21	Isis Pharmaceuticals, Inc.	Bicyclic cyclohexose nucleic acid analogs
US8927553B2 (en)	2009-08-10	2015-01-06	Daljit Singh Dhanoa	Deuterium-enriched alkyl sulfonamides and uses thereof
NZ714887A (en)	2009-09-11	2019-07-26	Ionis Pharmaceuticals Inc	Modulation of huntingtin expression
ES2586683T3 (es)	2009-09-16	2016-10-18	Wave Life Sciences Japan, Inc.	Grupo protector novedoso para sintetizar ARN y derivados del mismo
WO2011038288A1 (en)	2009-09-25	2011-03-31	Isis Pharmaceuticals, Inc.	Modulation of ttc39 expression to increase hdl
ES2426407T3 (es)	2009-10-15	2013-10-23	Pfizer Inc.	Compuestos de pirrolo[2,3-d]pirimidina
EP2512246B1 (en)	2009-12-17	2015-09-30	Merck Sharp & Dohme Corp.	Aminopyrimidines as syk inhibitors
CN102812361A (zh)	2009-12-28	2012-12-05	阿茨拉实验室有限公司	诊断凝胶组合物、制造诊断凝胶组合物的方法
CN102753186B (zh)	2010-01-08	2016-09-14	Isis制药公司	血管生成素样3表达的调节
US8750507B2 (en)	2010-01-25	2014-06-10	Cisco Technology, Inc.	Dynamic group creation for managed key servers
CA2789038A1 (en)	2010-02-08	2011-08-11	Isis Pharmaceuticals, Inc.	Selective reduction of allelic variants
US8957040B2 (en)	2010-02-08	2015-02-17	Isis Pharmaceuticals, Inc.	Selective reduction of allelic variants
DK2534149T3 (da)	2010-02-10	2015-01-05	Glaxosmithkline Llc	6-amino-2-{ [ (1s)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8h-purin-8-on-maleat
JP5847700B2 (ja)	2010-03-05	2016-01-27	株式会社ＷａｖｅＬｉｆｅＳｃｉｅｎｃｅｓＪａｐａｎ	リボヌクレオシドホスホロチオエートの製造方法
WO2011127175A1 (en)	2010-04-06	2011-10-13	Isis Pharmaceuticals, Inc.	Modulation of cd130 (gp130) expression
CN102844434A (zh)	2010-04-07	2012-12-26	Isis制药公司	Cetp表达的调节
WO2011133871A2 (en)	2010-04-22	2011-10-27	Alnylam Pharmaceuticals, Inc.	5'-end derivatives
EP2601204B1 (en)	2010-04-28	2016-09-07	Ionis Pharmaceuticals, Inc.	Modified nucleosides and oligomeric compounds prepared therefrom
WO2011139699A2 (en)	2010-04-28	2011-11-10	Isis Pharmaceuticals, Inc.	5' modified nucleosides and oligomeric compounds prepared therefrom
US20130156845A1 (en)	2010-04-29	2013-06-20	Alnylam Pharmaceuticals, Inc.	Lipid formulated single stranded rna
GB201008902D0 (en)	2010-05-27	2010-07-14	Imp Innovations Ltd	Membrane enhanced polymer sythesis
JP2013541510A (ja)	2010-08-31	2013-11-14	メルク・シャープ・エンド・ドーム・コーポレイション	新規の単一の化学物質、およびオリゴヌクレオチドの送達方法
JP5868324B2 (ja)	2010-09-24	2016-02-24	株式会社Wave Life Sciences Japan	不斉補助基
CN103080314B (zh)	2010-09-30	2016-04-13	Lsip基金运营联合公司	显性突变基因表达抑制剂
KR101381048B1 (ko)	2010-10-20	2014-04-14	씨제이제일제당 (주)	Ｏ-포스포세린 생산 균주 및 이로부터 생산된 ｏ-포스포세린으로부터 ｌ-시스테인 또는 이의 유도체의 생산방법
WO2012058210A1 (en)	2010-10-29	2012-05-03	Merck Sharp & Dohme Corp.	RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
WO2012058693A2 (en) *	2010-10-29	2012-05-03	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibition of pcsk9 genes
CA2817256A1 (en)	2010-11-12	2012-05-18	The General Hospital Corporation	Polycomb-associated non-coding rnas
JP6093924B2 (ja)	2010-11-30	2017-03-15	株式会社Wave Life Sciences Japan	２’−ｏ−修飾ｒｎａ
EP2673361B1 (en)	2011-02-08	2016-04-13	Ionis Pharmaceuticals, Inc.	Oligomeric compounds comprising bicyclic nucleotides and uses thereof
WO2012109667A1 (en)	2011-02-12	2012-08-16	University Of Iowa Research Foundation	Therapeutic compounds
US9353371B2 (en)	2011-05-02	2016-05-31	Ionis Pharmaceuticals, Inc.	Antisense compounds targeting genes associated with usher syndrome
FR2975600B1 (fr)	2011-05-24	2013-07-05	Assist Publ Hopitaux De Paris	Agents pour le traitement de tumeurs
CN103796657B (zh)	2011-07-19	2017-07-11	波涛生命科学有限公司	合成官能化核酸的方法
US10202599B2 (en)	2011-08-11	2019-02-12	Ionis Pharmaceuticals, Inc.	Selective antisense compounds and uses thereof
US20140080896A1 (en)	2011-08-30	2014-03-20	The Regents Of The University Of California	Identification of small molecules that facilitate therapeutic exon skipping
JP2015502365A (ja)	2011-12-12	2015-01-22	オンコイミューニン，インコーポレイティド	オリゴヌクレオチドのイン−ビボ送達
CN102675386B (zh)	2011-12-24	2014-07-02	河南科技大学	一种龙胆苦苷分离提纯方法
WO2013134558A1 (en)	2012-03-07	2013-09-12	The Texas A & M University System	Cancer treatment targeting non-coding rna overexpression
KR20130114435A (ko)	2012-04-09	2013-10-17	삼성전자주식회사	다수의 전극을 갖는 생분자 검출 장치
US9284344B2 (en)	2012-05-30	2016-03-15	Hokkaido System Science Co., Ltd.	Oligonucleotide synthesis method using highly dispersible liquid-phase support
KR102213609B1 (ko)	2012-07-13	2021-02-08	웨이브 라이프 사이언시스 리미티드	키랄 제어
CA2879066C (en)	2012-07-13	2019-08-13	Shin Nippon Biomedical Laboratories, Ltd.	Chiral nucleic acid adjuvant
PL2872485T3 (pl)	2012-07-13	2021-05-31	Wave Life Sciences Ltd.	Asymetryczna grupa pomocnicza
AU2013299717B2 (en)	2012-08-06	2018-06-28	Alnylam Pharmaceuticals, Inc.	Carbohydrate conjugated RNA agents and process for their preparation
CN104736551B (zh)	2012-08-15	2017-07-28	Ionis制药公司	使用改进的封端方案制备寡聚化合物的方法
EP3459549B1 (en)	2012-10-12	2022-04-06	Ionis Pharmaceuticals, Inc.	Selective antisense compounds and uses thereof
CN104837996A (zh)	2012-11-15	2015-08-12	罗氏创新中心哥本哈根有限公司	抗apob反义缀合物化合物
WO2014080004A1 (en)	2012-11-26	2014-05-30	Santaris Pharma A/S	Compositions and methods for modulation of fgfr3 expression
WO2014118272A1 (en)	2013-01-30	2014-08-07	Santaris Pharma A/S	Antimir-122 oligonucleotide carbohydrate conjugates
AU2014211406B2 (en)	2013-01-30	2019-07-18	Roche Innovation Center Copenhagen A/S	LNA oligonucleotide carbohydrate conjugates
WO2014121287A2 (en)	2013-02-04	2014-08-07	Isis Pharmaceuticals, Inc.	Selective antisense compounds and uses thereof
DK2992098T3 (da)	2013-05-01	2019-06-17	Ionis Pharmaceuticals Inc	Sammensætninger og fremgangsmåder til modulering af hbv- og ttr-ekspression
DK3015467T3 (da)	2013-05-24	2025-02-10	Ajinomoto Kk	Morpholino-oligonukleotidfremstillingsfremgangsmåde
CN105247052A (zh)	2013-05-24	2016-01-13	罗氏创新中心哥本哈根有限公司	B-细胞cll/淋巴瘤11a(bcl11a)的寡核苷酸调节剂及其用途
HUE048738T2 (hu)	2013-06-27	2020-08-28	Roche Innovation Ct Copenhagen As	Antiszensz oligomerek és konjugátumok, amelyek a PCK9-t célozzák meg
TW202246503A (zh)	2013-07-19	2022-12-01	美商百健Ｍａ公司	用於調節τ蛋白表現之組合物
EP3024936B1 (en)	2013-07-25	2019-09-04	Exicure, Inc.	Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
EP3052521A1 (en)	2013-10-03	2016-08-10	Moderna Therapeutics, Inc.	Polynucleotides encoding low density lipoprotein receptor
WO2015051366A2 (en)	2013-10-04	2015-04-09	Novartis Ag	Novel formats for organic compounds for use in rna interference
WO2015070212A1 (en)	2013-11-11	2015-05-14	Sangamo Biosciences, Inc.	Methods and compositions for treating huntington's disease
MX2016005855A (es)	2013-11-14	2016-07-13	Roche Innovation Ct Copenhagen As	Compuestos de conjugados antisentido de apolipoproteina b (apob).
EP3053585A1 (en)	2013-12-13	2016-08-10	Moderna Therapeutics, Inc.	Alternative nucleic acid molecules and uses thereof
US10322173B2 (en)	2014-01-15	2019-06-18	Shin Nippon Biomedical Laboratories, Ltd.	Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
JPWO2015108048A1 (ja)	2014-01-15	2017-03-23	株式会社新日本科学	抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
JPWO2015108047A1 (ja)	2014-01-15	2017-03-23	株式会社新日本科学	免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
BR112016016400A2 (pt)	2014-01-16	2017-10-03	Wave Life Sciences Ltd	Composições de oligonucleotídeos quiralmente controlados, seu uso, sua composição farmacêutica, e métodos
WO2015168172A1 (en)	2014-04-28	2015-11-05	Isis Pharmaceuticals, Inc.	Linkage modified oligomeric compounds
US9382540B2 (en)	2014-05-01	2016-07-05	Isis Pharmaceuticals, Inc	Compositions and methods for modulating angiopoietin-like 3 expression
WO2015171932A1 (en)	2014-05-08	2015-11-12	Sangamo Biosciences, Inc.	Methods and compositions for treating huntington's disease
EP3146051B8 (en)	2014-05-20	2019-11-27	University of Iowa Research Foundation	Huntington's disease therapeutic compounds
US20160017327A1 (en)	2014-07-11	2016-01-21	The Johns Hopkins University	Phosphorodiamidate morpholino oligomers (pmos) and their use in suppression of mutant huntingtin expression and attenuation of neurotoxicity
US20170204152A1 (en)	2014-07-16	2017-07-20	Moderna Therapeutics, Inc.	Chimeric polynucleotides
EP2982758A1 (en)	2014-08-04	2016-02-10	Centre Hospitalier Universitaire Vaudois (CHUV)	Genome editing for the treatment of huntington's disease
WO2016027168A2 (en)	2014-08-20	2016-02-25	Lifesplice Pharma Llc	Splice modulating oligonucleotides and methods of use thereof
IL316808A (en)	2014-08-20	2025-01-01	Alnylam Pharmaceuticals Inc	Modified double-stranded RNA materials and their uses
WO2016037191A1 (en)	2014-09-05	2016-03-10	Health Research, Inc.	Use of huntingtin-derived plasmids and peptides for active immunization as a huntington's disease (hd) therapeutic
WO2016079183A1 (en)	2014-11-19	2016-05-26	Roche Innovation Center Copenhagen A/S	Lna chiral phosphorothioates
US10815481B2 (en)	2014-12-16	2020-10-27	Roche Innovation Center Copenhagen A/S	Chiral library screen
HRP20190992T1 (hr)	2014-12-24	2019-09-20	Uniqure Ip B.V.	Suprimiranje gena za huntingtin inducirano s rnai
US9688707B2 (en)	2014-12-30	2017-06-27	Ionis Pharmaceuticals, Inc.	Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
WO2016127002A1 (en)	2015-02-04	2016-08-11	Bristol-Myers Squibb Company	Lna oligonucleotides with alternating flanks
CN115181778A (zh)	2015-02-04	2022-10-14	百时美施贵宝公司	选择治疗性分子的方法
CR20170406A (es)	2015-02-10	2017-11-14	Genzyme Corp	Arni variante
CA2976445A1 (en)	2015-02-13	2016-08-18	Alnylam Pharmaceuticals, Inc.	Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
WO2016138017A1 (en)	2015-02-23	2016-09-01	Ionis Pharmaceuticals, Inc.	Compounds and methods for increasing antisense activity
WO2016141236A1 (en)	2015-03-03	2016-09-09	Ionis Pharmaceuticals, Inc.	Compositions for modulating mecp2 expression
WO2016154096A1 (en)	2015-03-20	2016-09-29	Ionis Pharmaceuticals, Inc.	Modulation of smggds expression
PL3277814T3 (pl)	2015-04-03	2020-11-30	University Of Massachusetts	Związki oligonukleotydowe ukierunkowane na mrna huntingtyny
WO2016164896A2 (en)	2015-04-10	2016-10-13	Ionis Pharmaceuticals, Inc.	Modulation of smn expression
US10407678B2 (en)	2015-04-16	2019-09-10	Ionis Pharmaceuticals, Inc.	Compositions for modulating expression of C9ORF72 antisense transcript
WO2016209862A1 (en)	2015-06-23	2016-12-29	Alnylam Pharmaceuticals, Inc.	Glucokinase (gck) irna compositions and methods of use thereof
WO2017004261A1 (en)	2015-06-29	2017-01-05	Ionis Pharmaceuticals, Inc.	Modified crispr rna and modified single crispr rna and uses thereof
MX2018000412A (es)	2015-07-10	2018-03-14	Ionis Pharmaceuticals Inc	Moduladores de diaciglicerol aciltransferasa 2 (dgat2).
WO2017011286A1 (en)	2015-07-10	2017-01-19	Alnylam Pharmaceuticals, Inc.	Insulin-like growth factor binding protein, acid labile subunit (igfals) and insulin-like growth factor 1 (igf-1) irna compositions and methods of use thereof
CA3205381A1 (en)	2015-07-17	2017-01-26	Alnylam Pharmaceuticals, Inc.	Multi-targeted single entity conjugates
IL320434A (en)	2015-07-22	2025-06-01	Wave Life Sciences Ltd	Oligonucleotide preparations and methods
WO2017019660A1 (en)	2015-07-27	2017-02-02	Alnylam Pharmaceuticals, Inc.	Xanthine dehydrogenase (xdh) irna compositions and methods of use thereof
PT3329002T (pt)	2015-07-31	2021-01-12	Alnylam Pharmaceuticals Inc	Composições de iarn de transtirretina (ttr) e métodos de seu uso para tratamento ou prevenção de doenças associadas à ttr
JP6835826B2 (ja)	2015-08-24	2021-02-24	ロシュイノベーションセンターコペンハーゲンエーエス	Ｌｎａ−ｇプロセス
CN108348541A (zh)	2015-08-25	2018-07-31	阿尔尼拉姆医药品有限公司	用于治疗前蛋白转化酶枯草杆菌蛋白酶kexin(pcsk9)基因相关障碍的方法和组合物
CA2996873A1 (en)	2015-09-02	2017-03-09	Alnylam Pharmaceuticals, Inc.	Programmed cell death 1 ligand 1 (pd-l1) irna compositions and methods of use thereof
US10577388B2 (en)	2015-10-02	2020-03-03	Roche Innovation Center Copenhagen A/S	Oligonucleotide conjugation process
IL295755A (en)	2015-10-09	2022-10-01	Wave Life Sciences Ltd	Oligonucleotide compositions and methods thereof
US10955407B2 (en)	2015-10-22	2021-03-23	Roche Innovation Center Copenhagen A/S	In vitro toxicity screening assay
WO2017068087A1 (en)	2015-10-22	2017-04-27	Roche Innovation Center Copenhagen A/S	Oligonucleotide detection method
LT3374509T (lt)	2015-11-12	2021-03-10	F. Hoffmann-La Roche Ag	Oligonukleotidai, skirti sukelti iš tėvo paveldėto ube3a raišką
CN108779132B (zh)	2016-03-13	2022-04-15	波涛生命科学有限公司	用于亚磷酰胺和寡核苷酸合成的组合物和方法
RU2747822C2 (ru)	2016-03-14	2021-05-14	Ф. Хоффманн-Ля Рош Аг	Олигонуклеотиды для понижения экспрессии pd-l1
WO2017157672A1 (en)	2016-03-18	2017-09-21	Roche Innovation Center Copenhagen A/S	Acyl-protected l-lna-guanosine monomers
WO2017178656A1 (en)	2016-04-14	2017-10-19	Roche Innovation Center Copenhagen A/S	TRITYL-MONO-GalNAc COMPOUNDS AND THEIR USE
EP3452596A4 (en)	2016-05-04	2020-03-18	Wave Life Sciences Ltd.	OLIGONUCLEOTIDE COMPOSITIONS AND RELATED METHODS
CN109462995A (zh)	2016-05-04	2019-03-12	波涛生命科学有限公司	生物活性剂的方法和组合物
EP3455232B1 (en)	2016-05-12	2020-05-06	Roche Innovation Center Copenhagen A/S	Enhanced coupling of stereodefined oxazaphospholidine phosphoramidite monomers to nucleoside or oligonucleotide
EP3455354B1 (en)	2016-05-13	2023-07-12	Roche Diagnostics GmbH	Protein-based sample collection matrices and devices
JP2019520339A (ja)	2016-06-03	2019-07-18	ウェイブライフサイエンシズリミテッドＷａｖｅＬｉｆｅＳｃｉｅｎｃｅｓＬｔｄ．	オリゴヌクレオチド、その組成物および方法
WO2018022473A1 (en)	2016-07-25	2018-02-01	Wave Life Sciences Ltd.	Phasing
US11873316B2 (en)	2016-11-23	2024-01-16	Wave Life Sciences Ltd.	Compositions and methods for phosphoramidite and oligonucleotide synthesis
CN120330183A (zh)	2017-06-02	2025-07-18	波涛生命科学有限公司	寡核苷酸组合物及其使用方法
CA3065523A1 (en)	2017-06-02	2018-12-06	Wave Life Sciences Ltd.	Oligonucleotide compositions and methods of use thereof
JP2020522510A (ja)	2017-06-02	2020-07-30	ウェイブライフサイエンシズリミテッドＷａｖｅＬｉｆｅＳｃｉｅｎｃｅｓＬｔｄ．	オリゴヌクレオチド組成物及びその使用方法
US11718638B2 (en)	2017-06-21	2023-08-08	Wave Life Sciences Ltd.	Compounds, compositions and methods for synthesis
WO2019002237A1 (en)	2017-06-28	2019-01-03	Roche Innovation Center Copenhagen A/S	METHOD OF MULTIPLE COUPLING AND OXIDATION
EP3664816A4 (en)	2017-08-08	2021-05-19	Wave Life Sciences Ltd.	OLIGONUCLEOTIDE COMPOSITIONS AND RELATED PROCESSES
CA3072110A1 (en)	2017-09-18	2019-03-21	Wave Life Sciences Ltd.	Technologies for oligonucleotide preparation
EP3694530A4 (en)	2017-10-12	2021-06-30	Wave Life Sciences Ltd.	COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES
EP3728281A1 (en)	2017-12-21	2020-10-28	Alnylam Pharmaceuticals Inc.	Chirally-enriched double-stranded rna agents
SG11202009877XA (en)	2018-04-12	2020-11-27	Wave Life Sciences Ltd	Oligonucleotide compositions and methods of use thereof
US12391942B2 (en)	2018-05-11	2025-08-19	Wave Life Sciences Ltd.	Oligonucleotide compositions and methods of use thereof
JP2022513719A (ja)	2018-12-06	2022-02-09	ウェイブライフサイエンシズリミテッド	オリゴヌクレオチド組成物及びその方法
CN113423385A (zh)	2019-02-01	2021-09-21	波涛生命科学有限公司	寡核苷酸组合物及其方法
FR3093595B1 (fr)	2019-03-07	2022-03-11	Thales Sa	Systeme de calibration depuis le sol d'une charge utile d'un satellite
JP2022525541A (ja)	2019-03-20	2022-05-17	ウェイブライフサイエンシズリミテッド	オリゴヌクレオチド調製に有用な技術
WO2020196662A1 (ja)	2019-03-25	2020-10-01	国立大学法人東京医科歯科大学	二本鎖核酸複合体及びその使用
SG11202111387YA (en)	2019-04-25	2021-11-29	Wave Life Sciences Ltd	Oligonucleotide compositions and methods of use thereof
BR112021021203A2 (pt)	2019-04-25	2022-01-04	Wave Life Sciences Ltd	Oligonucleotídeo; composição de oligonucleotídeo quiralmente controlada; composição farmacêutica; método para prevenir, tratar ou melhorar uma afecção, distúrbio ou doença relacionada a ush2a e/ou prevenir, atrasar o início, desenvolvimento e/ou progresso, e/ou tratar uma afecção, distúrbio ou doença relacionada a ush2a em um indivíduo suscetível à mesma ou que sofre da mesma; método para aumentar o nível de salto de um éxon prejudicial em uma transcrição de gene ush2a ou seu produto de gene em uma célula; método para prevenir, atrasar o início ou progressão de, tratar ou melhorar uma afecção, distúrbio ou doença relacionada a ush2a em um indivíduo suscetível à mesma ou que sofre da mesma; método para saltar um éxon prejudicial 13 em um alelo de ush2a em um indivíduo; método para produzir ou aumentar o nível de um éxon de proteína ush2a com salto 13 em um sistema; e composto, oligonucleotídeo, composição ou método
EP3965780A4 (en)	2019-05-09	2023-10-25	Wave Life Sciences Ltd.	OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE
JP2022550915A (ja)	2019-10-06	2022-12-05	ウェイブライフサイエンシズリミテッド	オリゴヌクレオチド組成物及びその使用方法
JP7766589B2 (ja)	2019-10-06	2025-11-10	ウェイブライフサイエンシズリミテッド	オリゴヌクレオチド組成物及びその使用方法
JP2023515862A (ja)	2020-03-01	2023-04-14	ウェイブライフサイエンシズリミテッド	オリゴヌクレオチド組成物及びその方法
AU2021277407A1 (en)	2020-05-22	2022-11-17	Wave Life Sciences Ltd.	Oligonucleotide compositions and methods thereof

2013
- 2013-07-12 KR KR1020157003995A patent/KR102213609B1/ko active Active
- 2013-07-12 RU RU2015104762A patent/RU2015104762A/ru not_active Application Discontinuation
- 2013-07-12 MX MX2015000577A patent/MX2015000577A/es unknown
- 2013-07-12 EP EP13817244.0A patent/EP2872147B1/en active Active
- 2013-07-12 WO PCT/US2013/050407 patent/WO2014012081A2/en not_active Ceased
- 2013-07-12 CN CN202010516947.3A patent/CN112007045B/zh active Active
- 2013-07-12 EP EP22215059.1A patent/EP4219516A3/en active Pending
- 2013-07-12 KR KR1020247032351A patent/KR20240148947A/ko active Pending
- 2013-07-12 SG SG10201912895PA patent/SG10201912895PA/en unknown
- 2013-07-12 ES ES13817244T patent/ES2940887T3/es active Active
- 2013-07-12 SG SG11201500232UA patent/SG11201500232UA/en unknown
- 2013-07-12 JP JP2015521874A patent/JP6453212B2/ja active Active
- 2013-07-12 US US14/414,614 patent/US9982257B2/en active Active
- 2013-07-12 CA CA2878945A patent/CA2878945A1/en active Pending
- 2013-07-12 DK DK13817244.0T patent/DK2872147T3/da active
- 2013-07-12 PL PL13817244.0T patent/PL2872147T3/pl unknown
- 2013-07-12 AU AU2013289880A patent/AU2013289880B2/en active Active
- 2013-07-12 SG SG10201700283WA patent/SG10201700283WA/en unknown
- 2013-07-12 KR KR1020227034058A patent/KR102712879B1/ko active Active
- 2013-07-12 CN CN201380047876.5A patent/CN104661664B/zh active Active
- 2013-07-12 KR KR1020217003318A patent/KR102450907B1/ko active Active
2015
- 2015-01-11 IL IL236621A patent/IL236621B/en active IP Right Grant
- 2015-01-13 CL CL2015000092A patent/CL2015000092A1/es unknown
2017
- 2017-03-17 US US15/462,787 patent/US10590413B2/en active Active
2018
- 2018-07-13 AU AU2018205183A patent/AU2018205183B2/en active Active
- 2018-12-12 JP JP2018233004A patent/JP7004637B2/ja active Active
2019
- 2019-12-17 US US16/717,986 patent/US11643657B2/en active Active
2020
- 2020-10-01 AU AU2020244546A patent/AU2020244546B2/en active Active
2022
- 2022-01-04 JP JP2022000295A patent/JP7625544B2/ja active Active
- 2022-12-19 AU AU2022291426A patent/AU2022291426A1/en not_active Abandoned
2023
- 2023-05-05 US US18/313,032 patent/US20240229026A1/en active Pending
2025
- 2025-01-22 JP JP2025009044A patent/JP2025066783A/ja active Pending
- 2025-02-28 AU AU2025201455A patent/AU2025201455A1/en active Pending

Also Published As

Publication number	Publication date
MX2015000577A (es)	2015-08-14
US10590413B2 (en)	2020-03-17
KR20150036642A (ko)	2015-04-07
EP4219516A3 (en)	2024-01-10
KR102450907B1 (ko)	2022-10-04
KR20240148947A (ko)	2024-10-11
WO2014012081A2 (en)	2014-01-16
US20240229026A1 (en)	2024-07-11
EP2872147B1 (en)	2022-12-21
JP2015528002A (ja)	2015-09-24
JP7625544B2 (ja)	2025-02-03
US20170275621A1 (en)	2017-09-28
SG10201700283WA (en)	2017-03-30
JP6453212B2 (ja)	2019-01-16
CN112007045B (zh)	2026-01-06
HK1210595A1 (en)	2016-04-29
US11643657B2 (en)	2023-05-09
CN112007045A (zh)	2020-12-01
AU2020244546B2 (en)	2022-09-22
SG10201912895PA (en)	2020-02-27
AU2018205183A1 (en)	2018-08-02
EP2872147A2 (en)	2015-05-20
CA2878945A1 (en)	2014-01-16
JP2025066783A (ja)	2025-04-23
KR102712879B1 (ko)	2024-10-04
KR20210016078A (ko)	2021-02-10
AU2022291426A1 (en)	2023-02-02
SG11201500232UA (en)	2015-04-29
KR20220139425A (ko)	2022-10-14
IL236621A0 (en)	2015-02-26
AU2025201455A1 (en)	2025-03-20
US20210130821A1 (en)	2021-05-06
CN104661664B (zh)	2020-07-03
CL2015000092A1 (es)	2015-08-07
PL2872147T3 (pl)	2023-09-25
AU2018205183B2 (en)	2020-07-02
CN104661664A (zh)	2015-05-27
WO2014012081A3 (en)	2014-03-06
RU2015104762A3 (da)	2018-08-31
EP4219516A2 (en)	2023-08-02
AU2020244546A1 (en)	2020-10-29
RU2015104762A (ru)	2018-08-31
AU2013289880A1 (en)	2015-02-05
US20150211006A1 (en)	2015-07-30
JP7004637B2 (ja)	2022-02-04
KR102213609B1 (ko)	2021-02-08
AU2013289880B2 (en)	2018-08-02
US9982257B2 (en)	2018-05-29
JP2019069971A (ja)	2019-05-09
JP2022050518A (ja)	2022-03-30
EP2872147A4 (en)	2016-01-20
ES2940887T3 (es)	2023-05-12
IL236621B (en)	2019-12-31

Publication	Publication Date	Title
DK2872147T3 (da)	2023-02-20	Fremgangsmåde til fremstilling af kirale oligonukleotider
DK2895156T3 (da)	2019-07-15	Fremgangsmåde til fremstilling af terapeutiske nanopartikler
DK2879718T3 (da)	2023-06-19	Proces til fremstilling af kulhydratkonjugerede RNA-stoffer
DK3777840T3 (da)	2025-06-02	Rna-formulering til immunterapi
DK2837629T3 (da)	2017-06-19	Fremgangsmåde til syntetisering af sapropterindihydrochlorid
DK2718404T3 (da)	2021-04-26	Fremgangsmåde til fremstilling af flydende carbonhydrider
DK2772549T3 (da)	2019-08-19	Fremgangsmåde til detektering af genetisk variation
DK3225604T3 (da)	2019-06-17	Fremgangsmåde til fremstilling af flerlagsruder
LT2869563T (lt)	2018-07-10	Vaizdo entropinio dekodavimo būdas
DK2768796T3 (da)	2020-02-24	Fremgangsmåde til fremstilling af quinolin-derivater
DK2639050T3 (da)	2014-06-02	Fremgangsmåde til fremstilling af en artikel ved formning
DK2814849T3 (da)	2020-03-09	Fremgangsmåde til fremstilling af cyclodextrin-derivater
DK2861240T3 (da)	2020-09-28	Nukleinsyrer til behandling af allergier
DK2857019T3 (da)	2020-08-17	Fremgangsmåde til behandling af multipel sklerose
DK2876447T3 (da)	2020-02-24	Fremgangsmåde til detektering af cancer
DK2728009T3 (da)	2017-11-06	Fremgangsmåde til fremstilling af monosaccharider
DK3444238T3 (da)	2022-01-03	Fremgangsmåde til fremstilling af difluormethylenforbindelser
DK2536422T3 (da)	2014-07-28	Fremgangsmåder til behandling af diabetiske fodsår
DK2834229T3 (da)	2017-11-20	Fremgangsmåde til fremstilling af ccr3-inhibitorer
DK2809782T3 (da)	2017-11-20	Forbedret fremgangsmåde til fremstilling af makrokugler
LT3202769T (lt)	2019-12-10	Fosfaplatinos junginių gryninimo būdas
DK3398594T3 (da)	2024-09-23	Sammensætninger til forbedring af hjernefunktion
EP2641896A4 (en)	2015-06-24	SEPARATION
DK2920151T3 (da)	2017-11-13	Fremgangsmåde til fremstilling af carboxamider
DK2808346T3 (da)	2019-05-20	Fremgangsmåde til fremstilling af tørret biocellulose